1.0 INDIVIDUALS AT HIGH RISK FOR VACCINE PREVENTABLE DISEASES..............................................1
  1.1 HOUSEHOLD MEMBERS OF AN IMMUNOCOMPROMISED PERSON ........................................... 1
  1.2 GENERAL PRINCIPLES FOR IMMUNIZATION OF THE IMMUNOCOMPROMISED ........................................ 2
  1.3 IMMUNIZATION WITH INACTIVATED VACCINES ........................................................................2
  1.4 IMMUNIZATION WITH LIVE VACCINES .................................................................................. 2
  1.4.1 CONSIDERATION FOR MMR AND VARICELLA IMMUNIZATION OF IMMUNOCOMPROMISED INDIVIDUALS ...... 3

2.0 CHRONIC MEDICAL CONDITIONS ......................................................................................5
  2.1 BLEEDING DISORDERS ........................................................................................................ 5
  2.2 CARDIAC DISEASE ............................................................................................................. 6
  2.3 COCHLEAR IMPLANT ........................................................................................................... 6
  2.4 ASPLENIA – CONGENITAL, ACQUIRED OR FUNCTIONAL .................................................... 7
  2.5 CEREBROSPINAL FLUID DISORDERS .................................................................................. 8
  2.6 CYSTIC FIBROSIS .............................................................................................................. 8
  2.7 DIABETES MELLITUS .......................................................................................................... 8
  2.8 LIVER DISEASE ................................................................................................................ 9
  2.9 LUNG DISEASE ................................................................................................................ 9
  2.10 MALIGNANCIES / CANCER ............................................................................................... 10
  2.11 NEUROLOGICAL CONDITIONS THAT IMPEDE THE CLEARANCE OF RESPIRATORY/ORAL SECRETIONS .............. 11
    2.11.1 DEVELOPMENT OF A NEW NEUROLOGICAL CONDITION AT ANY TIME AFTER IMMUNIZATION ................ 11
    2.11.2 GUILLAIN-BARRÉ SYNDROME .................................................................................... 11
  2.12 RENAL DISEASE ............................................................................................................ 12
  2.13 SICKLE CELL DISEASE .................................................................................................... 13

3.0 IMMUNOCOMPROMISED CONDITIONS .............................................................................14
  3.1 CONGENITAL IMMUNODEFICIENCY .................................................................................... 14
  3.2 ACQUIRED COMPLEMENT DEFICIENCY .............................................................................. 14
  3.3 HUMAN IMMUNODEFICIENCY VIRUS ............................................................................... 15
  3.4 TRANSPLANT CANDIDATE OR RECIPIENT – ISLET CELL .................................................... 17
  3.5 TRANSPLANT CANDIDATE OR RECIPIENT – SOLID ORGAN/TISSUE .................................. 17
  3.6 TRANSPLANT RECIPIENT – HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) .................. 18
  3.7 MEDICAL TREATMENT .................................................................................................... 19
    3.7.1 HIGH DOSE CORTICOSTEROID THERAPY .................................................................. 19

4.0 POST-EXPOSURE .............................................................................................................21
  4.1 INFANT BORN TO HBsAg POSITIVE MOTHER OR HIGH RISK FOR HB ≥ 2000g .................. 21
  4.2 INFANT BORN TO HBsAg POSITIVE MOTHER OR HIGH RISK FOR HB < 2000g ............ 21
    4.2.1 HEPATITIS B INFANT IMMUNOPROPHYLAXIS PROTOCOL 1, 2 ...................................... 21
5.0 SPECIAL POPULATION

5.1 MEN WHO HAVE SEX WITH MEN

5.2 PREGNANCY

5.2.1 PREGNANCY

5.2.1.1 INACTIVATED VACCINES

5.2.1.2 LIVE VACCINES

5.2.1.3 PASSIVE IMMUNIZING AGENTS AND BLOOD PRODUCTS DURING PREGNANCY

5.2.2 BREASTFEEDING

6.0 OCCUPATION

6.1 CHILD CARE

6.2 HEALTH CARE WORKER – ELIGIBLE FOR PUBLICLY FUNDED VACCINES

6.2.1 STUDENTS OF HEALTH CARE PROFESSIONS – ELIGIBLE FOR PUBLICLY FUNDED VACCINES

6.3 HEALTH CARE WORKER – ELIGIBLE FOR PUBLICLY FUNDED VACCINES

7.0 OTHER POPULATIONS

7.1 PREMATURE BIRTH

7.2 INDIVIDUALS RECENTLY NEW TO CANADA

7.3 UNKNOWN OR UNCERTAIN IMMUNIZATION STATUS/INADEQUATE IMMUNIZATION RECORDS

7.4 TRAVELERS

8.0 REFERENCES

APPENDIX 7.1: PUBLICLY FUNDED VACCINE RECOMMENDATIONS FOR SPECIFIC POPULATIONS BY PANORAMA RISK FACTOR CATEGORY

APPENDIX 7.2: VARICELLA IMMUNIZATION REFERRAL FORM

APPENDIX 7.3: MMR IMMUNIZATION REFERRAL FORM

APPENDIX 7.4: HIGH DOSE HEPATITIS B IMMUNIZATION ALGORITHM - RENAL, HIV, CONGENITAL IMMUNODEFICIENCY DEFICIENCY [CID] CLIENTS

APPENDIX 7.5: INFANT HEPATITIS B PROPHYLAXIS RECORD REFERRAL FORM

APPENDIX 7.6: PUBLICLY FUNDED IMMUNIZATION SCHEDULE FOR ADULT POST-HEMATOPOIETIC STEM CELL TRANSPLANT

APPENDIX 7.7: TDAP IMMUNIZATION DECISION CHART FOR PREGNANT WOMEN

APPENDIX 7.8: PUBLICLY FUNDED IMMIGRANT AND REFUGEE IMMUNIZATION AND SEROLOGY RECOMMENDATIONS

APPENDIX 7.9: PUBLICLY FUNDED IMMUNIZATION SCHEDULE FOR ADULT SOLID ORGAN PRE-TRANSPLANT CANDIDATES

APPENDIX 7.10: PUBLICLY FUNDED IMMUNIZATION SCHEDULE FOR ADULT SOLID ORGAN POST-TRANSPLANT RECIPIENTS


#11: Populations Requiring Special Considerations

♦ Competency: Recognizes and responds to the unique immunization needs of certain population groups.
1.0 INDIVIDUALS AT HIGH RISK FOR VACCINE PREVENTABLE DISEASES

Individuals who have certain chronic medical conditions or who are immunocompromised related to disease or medical treatments are unable to mount adequate immune responses to vaccines. The cause of the altered immunocompetent state can be primary (inherited) or secondary (acquired), and it can be temporary or permanent. In these individuals, even a less than optimal immune response to a vaccine may provide protective benefits to reduce their high risk of morbidity and mortality from vaccine-preventable diseases.

Chronic medical condition examples:
- Cochlear implant candidate or recipient*
- Congenital or acquired or functional asplenia*
- Liver disease (including hepatitis B and C)
- Malignancies /cancer
- Renal disease

Immunocompromised condition examples:
- Acquired complement deficiency* or congenital immunodeficiency* involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell-mediated) immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
- Human immunodeficiency virus (HIV)*
- Immunosuppressive treatments (e.g., corticosteroids, chemotherapy, radiation therapy, post-organ-transplant therapy*, certain anti-rheumatic drugs, and drugs used for the management of inflammatory bowel disease)
- Transplant candidate or recipient - islet cell, solid organ* or tissue
- Transplant recipient - haematopoietic stem cell transplantation (HSCT)*

* These individuals have a very high risk of infection from encapsulated bacteria such as Streptococcus pneumonia, Neisseria meningitidis, and Haemophilus influenzae type b.

1.1 Household Members of an Immunocompromised Person

Immunization of household contacts provides important protection against transmission of disease in the household.
- Assess the immunization status of household contacts. Ensure routine immunizations are up-to-date.
- Ensure that opportunities to immunize are not missed for household contacts.
- Offer yearly influenza vaccine to all household contacts of immunocompromised individuals, regardless of whether or not the individual at high risk has been immunized.
- There are no general contraindications to immunization of household or close contacts of immunosuppressed individuals. Household and close contacts of immunocompromised individuals can be immunized with MMR, varicella, and rotavirus vaccines as the vaccine viruses are rarely transmitted to contacts.
- Wash hands well to prevent possible rotavirus transmission after changing a diaper, etc.
- No special precautions need to be taken post MMR immunization, regardless of whether or not a post-vaccine rash occurs.
- After varicella immunization, no special precautions need to be taken unless the vaccine recipient develops a post-varicella vaccination rash within 42 days of vaccine receipt.
- Vaccine recipients should keep the rash covered. If this is not possible, they should minimize contact with susceptible immunocompromised individuals for the duration of the rash.
1.2 General Principles for Immunization of the Immunocompromised

Maximize benefit while minimizing harm.

- There is potential for serious illness and death in the under-immunization of immunocompromised people and every effort should be made to ensure adequate protection through immunization.

Make no assumptions about susceptibility or protection.

- A history of childhood disease or previous vaccination may be irrelevant.

Immunize at the time when maximum immune response can be anticipated.

- Vaccines may be less effective when administered during the period of altered immunocompetence. Individuals who are fully immunized may remain at risk for vaccine-preventable diseases.
- Immunize early when immunologic decline is predictable.
- Delay immunization if the immunodeficiency is transient (if this can be done safely).
- Primary health care provider may decide to stop or reduce immunosuppressive therapy to permit better vaccine response (if this is appropriate).

Consider the vaccination environment broadly.

- Immunize household contacts (family and caregivers) when individuals need protection (e.g. against influenza).

Avoid live vaccines unless:

- Data are available to support their use.
- The risk of natural infection is greater than the risk of immunization.

Administer routine reinforcements (booster doses) as indicated.

- The degree and duration of vaccine-induced immunity are often reduced in immune compromised individuals.

Consider the use of passive immunizing agents. These include:

- Immune globulin (Ig);
- Intravenous immune globulin (IVIg); and
- Pathogen-specific immune globulin preparations (e.g., tetanus immune globulin).

1.3 Immunization with Inactivated Vaccines

There are no general contraindications to immunizing immunocompromised individuals with inactivated vaccines. Specific vaccine formulations (e.g., 40 µg HB vaccine for individuals with chronic renal disease) and/or specific immunization schedules may be recommended for particular conditions.

1.4 Immunization with Live Vaccines

The administration of live vaccines can cause serious adverse events in immunocompromised individuals because of the uncontrollable replication of the virus or bacterium. The decision to immunize an immunocompromised individual with a live vaccine can only be made following consultation with the physician most knowledgeable about the client’s current health status, their immunosuppressive disease, and the vaccine. This includes either the primary care physician most familiar with the client’s current medical status or a medical specialist.
Determine with the client which physician would be most familiar with their current health status. If the client is uncertain, consult the client’s specialist. Consult the most appropriate physician, and obtain a written referral regarding live vaccine administration to any individual whose immune system is compromised as the result of disease or therapy. Physician to physician (e.g., specialist and MHO) discussion and referral may occur, and documentation of recommendations should occur to communicate to public health staff. Refer to Appendix 7.2: Varicella Immunization Referral Form and Appendix 7.3: MMR Immunization Referral Form.

Many individuals with immunosuppressing conditions are immune to varicella because of earlier immunization or disease. Assess all immune suppressed clients 12 months of age and older for varicella susceptibility prior to immunization. Varicella susceptibility is defined as not having previously received a cohort-based varicella vaccine series; no documented serological evidence of immunity to the varicella zoster virus; or no lab-confirmed documentation of disease (e.g., culture from a pox viral swab).

1.4.1 Consideration for MMR and Varicella Immunization of Immunocompromised Individuals
Consult the most appropriate physician, as described in section 1.4 Immunization with Live Vaccines and obtain a written referral regarding live vaccine administration to any individual whose immune system is compromised as the result of disease or therapy.

Haematopoietic Stem Cell Transplant (HSCT) recipient:
- MMR and varicella vaccines may be considered if the client is two or more years post-transplant and there is no graft versus host disease and no immunosuppressive treatment.

High Doses of Oral Corticosteroid Therapy of More than 14 days Duration: (≥ 2 mg/kg per day or ≥ 20 mg of prednisone daily):
- Depending on immunization history, age, and susceptibility, MMR and varicella vaccines may be considered if the client is able to discontinue therapy for one month prior to immunization.

HIV Infection:
- Depending on immunization history, age, and susceptibility, upon consultation, the client’s specialist may approve MMR vaccine if no evidence of significant immune system compromise is present.
- Upon consultation, the client’s specialist may approve varicella vaccine for susceptible individuals 12 months and older with asymptomatic or mildly symptomatic HIV infection (CDC clinical category N, A or B and immunologic category 1 or 2) and with age–specific CD4 percentages of ≥ 15%.
- Varicella and MMR vaccines may be administered at the same visit provided adequate anatomical spacing is used.
- MMRV vaccine is not indicated for use in HIV infected individuals at this time.

Immunosuppressive medical treatments (e.g., chemotherapy, radiation therapy, certain antirheumatic drugs, and drugs used for the management of inflammatory bowel disease):
- Live vaccines are contraindicated during therapy but may be considered if only low doses of immunosuppressive drugs are required and there is significant risk of wild-type infection.
- Depending on immunization history, age, and susceptibility, MMR and varicella vaccines may be considered if three or more months have elapsed since immunosuppressive therapy was discontinued.
Congenital Immunodeficiency
- A family history of congenital immunodeficiency may not be evident in infants less than 12 months of age but may be documented as an overwhelming infection following a natural infection or receipt of a live vaccine in an older sibling or a sibling who may be deceased.
- Assess family history of these types of events prior to administering a live vaccine to an infant less than 12 months of age (e.g., MMR vaccine for an infant travelling to a measles endemic region). If such a history is present, live vaccines are contraindicated.

Isolated Immunodeficiencies (e.g., humoral (IG), neutrophil, or complement deficiency) or acquired complement deficiency:
- Depending on immunization history, age, and susceptibility, MMR and varicella vaccines may not be recommended.

Malignancies / Cancer:
- MMR and varicella vaccines are contraindicated until three or more month’s remission has elapsed and immunosuppressive therapy was discontinued.
- For clients with acute lymphocytic leukemia (ALL) – varicella vaccine is recommended if the client’s disease has been in remission for 12 or more months, the client’s total lymphocyte count is ≥ 1.2 X 10⁹/L, the client is not receiving radiation therapy, and maintenance chemotherapy can be withheld for 1 week before to 1 week after immunization.
- MMR and varicella vaccines are indicated according to the client’s immunization history, age, and susceptibility.

Renal Disease and Dialysis Clients:
- MMR and varicella vaccines are recommended depending on the client’s immunization history, age, and susceptibility given the possibility of receiving a kidney transplant in the future.

Transplant Candidate or Recipient – Islet cell, Solid Organ, Tissue:
- MMR and varicella vaccines are recommended for solid organ transplant candidates, depending on the client’s immunization history, age, and susceptibility.
- MMR and varicella vaccines are contraindicated for solid organ transplant recipients. MMR vaccine may be considered for seronegative females before pregnancy or two or more years post-transplantation if the individual is taking minimal immunosuppressive therapy.
2.0 CHRONIC MEDICAL CONDITIONS

2.1 Bleeding Disorders

- Individuals with bleeding disorders (e.g., haemophilia, thrombocytopenia) and those receiving anticoagulant therapy have an increased risk of bleeding (e.g., haematoma) after IM injections.
- Individuals who receive low doses of acetylsalicylic acid therapy or long-term anticoagulation (e.g., coumadin, heparin) are not considered to have a high risk of bleeding. However, manufacturers of varicella-containing vaccines (Var, MMRV) recommend that recipients should avoid using salicylates for 6 weeks after receiving a varicella-containing vaccine because of the association between Reye’s syndrome, natural varicella infection, and salicylates. **Those 18 years or younger on salicylate therapy must be able to discontinue it for 6 weeks post-vaccination and require a consultation with a medical specialist before receiving a varicella-containing vaccine.**
- Always consult with the child’s physician/specialist prior to MMR/MMRV immunization if they have had an episode of idiopathic thrombocytopenia that occurred within 6 weeks of a previous MMR/MMRV vaccine.
- MMR-associated ITP is rare, self-limiting and non-life threatening, and susceptible individuals with ITP should be immunized with MMR/MMRV at the recommended ages, after discussion with their physician/specialist. MMR/MMRV vaccination of unimmunized patients with ITP and re-vaccination of patients with previous non-vaccine or vaccine associated ITP, did not lead to recurrence of the thrombocytopenia. Those with either non-vaccine or vaccine-related ITP who have already received one dose of MMR/MMRV vaccine, vaccine titres may be checked to see if a second dose is required.
- If there is concern that the injection may stimulate bleeding, schedule it shortly after the administration of anti-haemophilia therapy. It is advisable to administer the vaccine approximately 3-4 hours after the anti-haemophilia therapy that decreases the risk of bleeding and haematoma. If bleeding does not stop after administering the vaccine, contact the MHO for further assistance (more anti-haemophilia therapy may be needed). Refer to SIM, Chapter 5, Section 3.5.1, Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus for further information.
- If vaccine efficacy is known to be the same for a vaccine whether it is administered SC or IM, administer the vaccine using the SC route.
- A fine gauge needle (23, 25, or 27 G) should be used. Z-track technique may be used to prevent bleeding. Use the rapid injection technique without aspiration. Apply direct pressure (without rubbing) to the injection site for two minutes or longer following immunization (CIG).
- Although currently available plasma-derived products are routinely tested for viral contamination prior to administration, any patient with a bleeding disorder should still be considered at higher risk of contracting hepatitis A or B and should be offered these vaccines. Even when recombinant therapeutic products are being used, immunization for hepatitis A and/or B is still recommended in case the recombinant supply is unavailable and patients are required to switch to plasma-derived products at short notice.

2.1A: Publicly Funded Vaccines¹ - Bleeding Disorders

<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| All routine vaccines | - Immunize according to routine schedule  
- Live attenuated influenza vaccine (LAIV e.g. FluMist®) is contraindicated for those on long-term aspirin or salicylate therapy. |
| HA | Non-immune individuals with bleeding disorders and others who receive repeated infusions of blood or blood products or plasma-derived replacement clotting factors. |
| HB | Non-immune individuals with bleeding disorders and others who receive repeated infusions of blood or blood products or plasma-derived replacement clotting factors. |

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
2.2 Cardiac Disease

Individuals with cardiac disease are at higher risk of influenza related complications and hospitalization, including pneumococcal infection and potentially the exacerbation of their underlying disease.

2.2A: Publicly Funded Vaccines\(^1\) - Cardiac Disease

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>All routine</td>
<td>- Complete a Pneu-C-13 series for medically high risk children</td>
</tr>
<tr>
<td></td>
<td>- 1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>- 1 dose for those 2 years and older</td>
</tr>
</tbody>
</table>

\(^1\) For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

2.3 Cochlear Implant

Cochlear implant recipients are at increased risk of developing bacterial meningitis, most commonly caused by *Streptococcus pneumoniae* bacteria. Cochlear implant candidates should be immunized at least 2 weeks prior to the cochlear implant.

2.3A: Publicly Funded Vaccines\(^1\) - Cochlear Implant

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>All routine</td>
<td>- Complete a Pneu-C-13 series for medically high risk children</td>
</tr>
<tr>
<td></td>
<td>- 1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>- 1 dose for those 2 years and older</td>
</tr>
<tr>
<td>Men-C-ACYW-135</td>
<td>- Complete an age-appropriate primary series.</td>
</tr>
<tr>
<td>Hib</td>
<td>- Immunization with an age-appropriate primary series should be completed for children less than 5 years.</td>
</tr>
<tr>
<td></td>
<td>- 1 dose Hib for people 5 years and older regardless of Hib immunization or Hib disease history</td>
</tr>
</tbody>
</table>

\(^1\) For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

\(^2\) A high-risk child 12 months of age and older, or an adult who is cohort eligible for a Men-C-C, does not require Men-C-C vaccine when they are eligible to receive Men-C-ACYW-135 vaccine.
2.4 Asplenia – Congenital, Acquired or Functional

A number of conditions may lead to functional asplenia (e.g., sickle cell disease, thalassemia major, celiac disease, inflammatory bowel disease, rheumatoid arthritis and other anemias and hemoglobinopathies). Individuals with any of these conditions need further investigation to determine whether their pre-existing condition is compromising their spleen function.

Asplenics are at increased risk for infection from pathogens, particularly those caused by encapsulated bacteria (e.g., pneumococcal, meningococcal, and Hib). For example, children who have sickle cell disease or have had a splenectomy are at increased risk for fulminant pneumococcal sepsis associated with high mortality rates. This risk continues throughout their lifespan.

Unimmunized individuals who have had a splenectomy in the past or who have functional hyposplenism should be immunized as soon as their condition is identified. Individuals undergoing an elective splenectomy should receive immunizations at least 2 weeks prior to surgery. In the case of an emergency splenectomy, administer all of the necessary vaccines two weeks after the splenectomy. If the individual is discharged earlier and there is a concern that he/she might not return, vaccination should be given before discharge.

2.4: Publicly Funded Vaccines ¹ - Asplenia – Congenital, Acquired, or Functional

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>All routine inactivated and live vaccines including influenza</td>
<td>• Complete a Pneu-C-13 series for medically high risk children</td>
</tr>
<tr>
<td></td>
<td>• 1 dose for Pneu-C-13 vaccine naïve individuals 5 years and older.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>• For those 2 years and older</td>
</tr>
<tr>
<td></td>
<td>• Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose.</td>
</tr>
<tr>
<td>Men-C-ACYW-135 ²</td>
<td>• Complete an age-appropriate primary series.</td>
</tr>
<tr>
<td></td>
<td>• Revaccination:</td>
</tr>
<tr>
<td></td>
<td>o If vaccinated at 6 years of age or younger, give a booster dose 3-5 years</td>
</tr>
<tr>
<td></td>
<td>after the last dose, and then give a booster dose every 5 years thereafter.</td>
</tr>
<tr>
<td></td>
<td>o If vaccinated at 7 years of age and older, give a booster dose not less than 5 years</td>
</tr>
<tr>
<td></td>
<td>after the last dose, and then give a booster dose every 5 years thereafter.</td>
</tr>
<tr>
<td>Hib</td>
<td>• Immunization with an age-appropriate primary series should be completed for children less than 5 years old.</td>
</tr>
<tr>
<td></td>
<td>• 1 dose Hib for people 5 years and older regardless of Hib immunization or Hib disease history.</td>
</tr>
<tr>
<td>Men-B4C</td>
<td>• Complete an age-appropriate primary series for all ages.</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
² A high-risk child 12 months of age and older, or an adult who is cohort eligible for a Men-C-C, does not required Men-C-C vaccine when they are eligible to receive Men-C-ACYW-135 vaccine.
2.5  Cerebrospinal Fluid Disorders
These individuals (usually from a congenital malformation, skull fracture or neurologic procedure) are at increased risk of invasive infections.

2.5A: Publicly Funded Vaccines¹ - Cerebrospinal Fluid Disorders

<table>
<thead>
<tr>
<th>All routine vaccines</th>
<th>Complete a Pneu-C-13 series for medically high risk children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>1 dose for those 2 years and older</td>
</tr>
<tr>
<td>Men-C-ACYW-135 ²</td>
<td>Complete an age-appropriate primary series.</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
² A high-risk child 12 months of age and older, or an adult who is cohort eligible for a Men-C-C, does not required Men-C-C vaccine when they are eligible to receive Men-C-ACYW-135 vaccine.

2.6  Cystic Fibrosis
Abnormal mucous is produced in the lungs of individuals with CF. It interferes with their breathing and they are more prone to serious lower respiratory tract and lung infections.

2.6A: Publicly Funded Vaccines¹ - Cystic Fibrosis

<table>
<thead>
<tr>
<th>All routine vaccines</th>
<th>Complete a Pneu-C-13 series for medically high risk children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>1 dose for those 2 years and older</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

2.7  Diabetes Mellitus
Individuals with diabetes mellitus type 1 or 2 are at high risk of influenza related complications, including pneumonia. In addition, individuals with longstanding diabetes mellitus often have complications such as cardiovascular, renal, and other organ dysfunction.

2.7A: Publicly Funded Vaccines - Diabetes Mellitus¹

<table>
<thead>
<tr>
<th>All routine vaccines</th>
<th>Complete a Pneu-C-13 series for medically high risk children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>1 dose for those 2 years and older</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
2.8  Liver Disease

Individuals with liver disease (including alcoholism, cirrhosis, hepatitis B, hepatitis C) are at increased risk for fulminant hepatitis A or more severe acute hepatitis B infection should infection occur. Chronic hepatitis C (HCV) infection develops in 70% - 80% of those infected. Chronic HCV may progress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Individuals with chronic liver disease are at increased risk of developing pneumococcal infection and severe pneumococcal disease and its complications. Immunization should be done early in the course of disease, as the immune response may be suboptimal in advanced liver disease.

2.8: Publicly Funded Vaccines<sup>1</sup> - Liver Disease

| All routine inactivated and live vaccines, including influenza | • Complete a Pneu-C-13 series for medically high risk children  
• 1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age. |
|---|---|
| Pneu-P-23 | • For those 2 years and older  
• Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose. |
| HA | Individuals who are non-immune to HA |
| HB | Individuals who are non-immune to HB |

<sup>1</sup> For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

2.9  Lung Disease

Individuals with lung disease (excluding asthma unless on high dose oral corticosteroid therapy) are at higher risk of influenza related complications and hospitalization, including pneumococcal infection and potentially the exacerbation of their underlying disease.

2.9A: Publicly Funded Vaccines<sup>1</sup> - Lung Disease

| All routine vaccines | • Complete a Pneu-C-13 series for medically high risk children  
• 1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneu-P-23</td>
<td>• 1 dose for those 2 years and older</td>
</tr>
</tbody>
</table>

<sup>1</sup> For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
2.10 Malignancies / Cancer

These individuals are at increased risk of vaccine-preventable diseases because of their underlying condition and medical treatment (e.g., chemotherapy, radiation therapy). There is a broad spectrum in the potential immunologic impact of cancer depending on cancer type and treatment used. Specific malignancies (e.g., Hodgkin and non-Hodgkin lymphomas) are associated with significant deficits in cell-mediated immunity, which can persist even after cure. Other malignancies such as multiple myeloma and B-cell chronic lymphocytic leukemia are associated with deficiencies in humoral immunity and susceptibility, particularly to infection with encapsulated bacteria. For most cancers, the main period of immune suppression is during or immediately following chemotherapy and/or radiation therapy when neutropenia and mucosal injury may be present. Refer to Section 3.7 Medical Treatment for immunization recommendations for the individual who is currently undergoing treatment.

*Please note that individuals who present as ‘cancer-free’ in the future do not qualify for additional vaccine doses (i.e., a second dose of Pneu-P-23) as their risk is the same as everyone else.

2.10A: Recommended Vaccines¹ – Malignancies / Cancer

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneu-P-23</td>
<td>• For those 2 years and older.</td>
</tr>
<tr>
<td></td>
<td>• Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose if they are not cancer-free*.</td>
</tr>
<tr>
<td>Hib</td>
<td>• Immunization with an age-appropriate primary series should be completed for children less than 5 years old</td>
</tr>
<tr>
<td></td>
<td>• 1 dose Hib for people 5 years and older regardless of Hib immunization or Hib disease history</td>
</tr>
<tr>
<td>Var</td>
<td>Specialist consultation required. Refer to Appendix 7.2: Varicella Immunization Referral Form.</td>
</tr>
<tr>
<td>MMR</td>
<td>Specialist consultation required. Refer to Appendix 7.3 MMR Immunization Referral Form.</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
2.11 Neurological Conditions that Impede the Clearance of Respiratory/Oral Secretions

Individuals with neurological conditions that impair the clearance of respiratory/oral secretions may be at higher risk of morbidity and mortality from bacterial and viral respiratory diseases and their sequelae. Those with neurologic disorders may be divided into two categories: those with a pre-existing neurologic condition prior to immunization, and those who developed symptoms of a new neurologic condition following immunization. Disorders that usually begin in infancy (e.g., cerebral palsy, spina bifida, seizure disorders, neuromuscular diseases and inborn errors of metabolism) may have symptoms identified before administration of the routine infant vaccines. Other disorders often appear later in childhood or adulthood (e.g., autism spectrum disorders, acute demyelinating encephalomyelitis, transverse myelitis, multiple sclerosis) and may appear coincidentally before or after administration of vaccines. There has been no causal relationship identified between any routine immunizations and autism spectrum disorders (MMR vaccine) or demyelinating disorders such as multiple sclerosis (hepatitis B vaccine).

2.11.A: Publicly Funded Vaccines¹ - Those with Neurological Conditions that Impede the Clearance of Respiratory/Oral Secretions

<table>
<thead>
<tr>
<th>All routine vaccines</th>
<th>Complete a Pneu-C-13 series for medically high risk children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>1 dose for those 2 years and older</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

2.11.1 Development of a New Neurological Condition at Any time After Immunization

Neurologic events that occur in the 8-12 weeks following immunization are temporally associated with immunization. Temporal association alone is not evidence that the vaccine caused the neurologic condition. Children who experience hypotonic-hyporesponsive events or prolonged crying after receiving a vaccine(s) may receive the next dose of vaccine according to schedule.

Individuals who develop encephalopathy or encephalitis within 7 days following immunization should be investigated. Continue to immunize according to routine schedule those individuals whose condition is found to have a different etiology and those who recover fully by the next scheduled immunization. Individuals with encephalopathy that persists and who have no alternative etiology should be referred to a specialist for further consultation. Continue with routine immunization schedule if their condition is stable and found not to relate to immunization.

2.11.2 Guillain-Barré Syndrome

A MHO should be consulted before immunizing an individual who has a history of Guillain-Barré syndrome (GBS) related or unrelated to immunization. Influenza and tetanus toxoid-containing vaccines are contraindicated for individuals who developed GBS within 6 weeks of a dose of these vaccines without any other cause being identified. Individuals who have developed GBS outside this interval or who have a different etiology confirmed may receive subsequent doses of tetanus and/or influenza vaccines upon consultation with the regional MHO.
2.12 Renal Disease
Renal disease includes predialysis, hemodialysis or peritoneal dialysis clients, those with nephrotic syndrome, and candidates for or recipients of a kidney transplant. Formulate immunization strategies early in the course of progressive kidney disease, particularly if transplantation and/or long term immunosuppressive therapy are being considered. All predialysis, hemodialysis, and peritoneal dialysis clients in hospital, community, home or self-care settings are eligible for this program. Vaccine administration should occur at the dialysis facility; however, in small communities the local health unit may arrange it.

Viral and bacterial infections are a major cause of morbidity and mortality in those who have chronic kidney disease or who are undergoing dialysis. Several issues put these individuals at increased risk of vaccine-preventable diseases:
- Vascular access catheters.
- Long-term peritoneal dialysis catheters.
- Immunosuppression prior to transplantation.
- Immune system compromise due to uremic state.
- Lower seroconversion rates to vaccines.
- Lower peak antibody titres following immunization.
- More rapid decline of antibody levels following immunization.

2.12A: Publicly Funded Vaccines ¹ - Renal Disease

<table>
<thead>
<tr>
<th>All routine inactivated and live vaccines, including influenza</th>
<th>Complete a Pneu-C-13 series for medically high risk children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 dose for Pneu-C-13 naïve children 60 months up to and including 17 years of age.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>For those 2 years and older</td>
</tr>
<tr>
<td></td>
<td>Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose.</td>
</tr>
<tr>
<td>HB</td>
<td>Refer to Appendix 7.4 High Dose Hepatitis B Immunization Algorithm</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
2.13 Sickle Cell Disease

Sickle cell disease may lead to functional asplenia. They are at increased risk for infection from pathogens, particularly those caused by encapsulated bacteria (e.g., pneumococcal, meningococcal, and Hib). Those who have sickle cell disease are at increased risk for fulminant pneumococcal sepsis associated with high mortality rates. This risk continues throughout their lifespan.

2.13A: Publicly Funded Vaccines\(^1\) – Sickle Cell Disease

| All routine inactivated and live vaccines including influenza | • Complete a Pneu-C-13 series for medically high risk children  
• 1 dose for Pneu-C-13 vaccine naïve individuals 5 years and older |
| --- | --- |
| Pneu-P-23 | • For those 2 years and older  
• Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose. |
| Men-C-ACYW-135 \(^2\) | • Complete an age-appropriate primary series.  
• Revaccination:  
  ○ If vaccinated at 6 years of age or younger, give a booster dose 3-5 years after the last dose, and then give a booster dose every 5 years thereafter.  
  ○ If vaccinated at 7 years of age and older, give a booster dose not less than 5 years after the last dose, and then give a booster dose every 5 years thereafter. |
| Hib | • Immunization with an age-appropriate primary series should be completed for children less than 5 years old.  
• 1 dose Hib for people 5 years and older regardless of Hib immunization or Hib disease history. |
| Men-B4C | • Complete an age-appropriate primary series for all ages. |

\(^{1}\) For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

\(^{2}\) A high-risk child 12 months of age and older, or an adult who is cohort eligible for a Men-C-C, does not required Men-C-C vaccine when they are eligible to receive Men-C-ACYW-135 vaccine.
3.0 IMMUNOCOMPROMISED CONDITIONS

3.1 Congenital Immunodeficiency

3.2 Acquired Complement Deficiency

Immunization of those with suspected or significant immunodeficiency should be performed only in consultation with medical experts. Congenital immunodeficiency includes disorders of B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement component deficiency (C5-C9, properdin, factor H, factor D), or phagocytic functions. Acquired complement immunodeficiency includes treatment with the terminal complement inhibitor eculizumab Soliris™. Upon medical specialist consultation, inactivated and component vaccines may be safely administered to individuals with all of these conditions, keeping in mind that many of the vaccine recipients will not develop an adequate immune response. Consider use of IVIg or pathogen-specific Ig if individual is exposed to vaccine-preventable disease. Live bacterial vaccines (e.g., oral typhoid vaccine, BCG) are contraindicated.

3.2A: Publicly Funded Vaccines - Congenital Immunodeficiency; Acquired Complement Deficiency

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>All routine inactivated vaccines including influenza</td>
<td>• Complete a Pneu-C-13 series for medically high-risk children.</td>
</tr>
<tr>
<td></td>
<td>• 1 dose for Pneu-C-13 vaccine naïve individuals 5 years and older</td>
</tr>
<tr>
<td>HB (Applies to Congenital Immunodeficiency only)</td>
<td>• Refer to Appendix 7.4 High Dose Hepatitis B Immunization Algorithm</td>
</tr>
<tr>
<td>Hib</td>
<td>• Immunization with an age-appropriate primary series should be completed for children less than 5 years old.</td>
</tr>
<tr>
<td></td>
<td>• 1 dose Hib for people 5 years and older regardless of Hib immunization or Hib disease history.</td>
</tr>
<tr>
<td>HPV-9</td>
<td>• 3-dose schedule: 0.5 mL IM at 0, 2, and 6 months for females and males aged 9 up to and including 26 years of age with the following risk factors (ineligible at 27th birthday):</td>
</tr>
<tr>
<td></td>
<td>o Immunocompromised – Acquired complement deficiency</td>
</tr>
<tr>
<td></td>
<td>o Immunocompromised – Congenital immunodeficiency</td>
</tr>
<tr>
<td></td>
<td>o Immunocompromised – HIV</td>
</tr>
<tr>
<td></td>
<td>o Immunocompromised – Related to Disease</td>
</tr>
<tr>
<td></td>
<td>o Immunocompromised – Treatment – Specify</td>
</tr>
<tr>
<td>Men-C-ACYW-135</td>
<td>• Complete an age-appropriate primary series.</td>
</tr>
<tr>
<td></td>
<td>• Revaccination:</td>
</tr>
<tr>
<td></td>
<td>o If vaccinated at 6 years of age or younger, give a booster dose 3-5 years after the last dose, and then give a booster dose every 5 years thereafter.</td>
</tr>
<tr>
<td></td>
<td>o If vaccinated at 7 years of age and older, give a booster dose not less than 5 years after the last dose, and then give a booster dose every 5 years thereafter.</td>
</tr>
<tr>
<td>Men-B4C</td>
<td>Complete an age-appropriate primary series for all ages.</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>• For those 2 years and older.</td>
</tr>
<tr>
<td></td>
<td>• Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose.</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Contraindicated.</td>
</tr>
<tr>
<td>Var</td>
<td>Specialist consultation required. Refer to Appendix 7.2: Varicella Immunization Referral Form.</td>
</tr>
<tr>
<td>MMR</td>
<td>Specialist consultation required. Refer to Appendix 7.3: MMR Immunization Referral Form.</td>
</tr>
</tbody>
</table>

1 For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

2 A high-risk child 12 months of age and older, or an adult who is cohort eligible for a Men-C-C, does not require Men-C-C vaccine when they are eligible to receive Men-C-ACYW-135 vaccine.
3.3 Human Immunodeficiency Virus

The ability of these individuals to respond to vaccine antigens is related to the degree of immunosuppression at the time of immunization and may be inadequate. Immune response may be positively affected by the antiretroviral therapy an individual with HIV is receiving. These persons could be susceptible to vaccine-preventable diseases, even after appropriate immunization, unless a recent serological test demonstrates adequate antibody concentrations. It is recommended to consult with the regional Medical Health Officer or an Infectious Disease (ID) specialist before administering live vaccines. Refer to Appendix 7.2: Varicella Immunization Referral Form and Appendix 7.3: MMR Immunization Referral Form.

HIV Immunodeficiency is defined as follows:
1. Severely immunocompromised: This includes persons with a current CD4 count of less than 200, those with a history of AIDS defining illness, or persons with clinical manifestations of symptomatic HIV.
2. Limited immune deficits: Asymptomatic HIV infection, persons with CD4 counts between 200 -500.
3. Not considered immunocompromised: Persons with HIV with a current CD4 count greater than 500.

NOTE: Always confirm the client’s state of immunosuppression with their specialist before proceeding with immunization.

Inactivated Vaccines
- There are no contraindications to the use of inactivated vaccines in these symptomatic and asymptomatic individuals at any time. However, the immune response to inactivated vaccines is suboptimal (depending on level of immunodeficiency). Incidence and severity of adverse reaction are not increased in these individuals.
- Post-immunization titres should be done one month after completing a primary hepatitis B or rabies series. Should the person not have mounted protective levels, further doses should be administered. The optimal timing of reinforcement (booster) doses for immunocompromised individuals who are at continued risk of HBV exposure and have mounted an initial response is not known. Periodic monitoring of anti-HBs may be considered, and booster doses provided if needed.

Live Attenuated Viral or Bacterial Vaccines
- As the client’s illness progresses, the immune system weakens and the effectiveness of immunization decreases while the risk associated with administering live vaccines increases.
- Rotavirus vaccine may be administered on schedule to infants regardless of their CD4 counts unless another contraindication exists.
- Those with HIV infection are at increased risk for complications from varicella and herpes zoster. Monovalent varicella vaccine should be considered for certain asymptomatic and mildly symptomatic HIV infected children 12 months of age and older. Consult with an Infectious Disease (ID) specialist before administering varicella vaccine to HIV infected individuals. Refer to Appendix 7.2: Varicella Immunization Referral Form.
- For those that received regular doses of intravenous immunoglobulin (IGIV), receipt of MMR and varicella vaccines should be considered approximately 14 days prior to the next scheduled dose of IGIV. Refer to SIM, Chapter 5, Section 3.5.1, Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus.
- MMRV and live attenuated influenza (LAIV) vaccines are contraindicated in the HIV client regardless of the degree of immunosuppression.
- Persons with HIV infection are at increased risk for severe complications from measles. MMR vaccine is recommended for those 12 months of age and older who are not considered severely immunocompromised. Eligible persons should receive two doses of MMR vaccine with a minimum 4 week interval separating the doses. Consult an Infectious Disease (ID) specialist before administering MMR vaccine to HIV infected individuals. Refer to Appendix 7.3: MMR Immunization Referral Form.
### 3.3A: Publicly Funded Vaccines and Immune Globulins \(^1\)– Human Immunodeficiency Virus

<table>
<thead>
<tr>
<th>Vaccines and Immune Globulins</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| **All routine vaccines**      | - Replace Men-C with Men-C-ACYW-135 at 12 months of age.  
                                - To receive inactivated influenza vaccine.  
| **Pneu-C-13**                 | - Complete a Pneu-C-13 series for medically high-risk children as per age recommendations.  
                                - 1 dose for Pneu-C-13 naïve individuals 5 years and older.  
| **HPV-9 3-dose schedule**     | For females and males aged 9 up to and including 26 years of age with the following risk factors (ineligible at 27\(^{th}\) birthday):  
                                - Immunocompromised – Acquired complement deficiency  
                                - Immunocompromised – Congenital immunodeficiency  
                                - Immunocompromised – HIV  
                                - Immunocompromised – Related to Disease  
                                - Immunocompromised – Treatment – Specify  
| **Men-B4C Adults 18 years and older ineligible** | - Complete an age appropriate series for children up to and including 17 years of age only.  
| **Men-C-ACYW-135 Adults 18 years and older ineligible** | - Complete an age appropriate series for children up to and including 17 years of age only.  
                                - Revaccination:  
                                - If vaccinated at 6 years of age or younger, give a booster dose 3-5 years after the last dose, and then give a booster dose every 5 years thereafter.  
                                - If vaccinated at 7 years of age and older, give a booster dose not less than 5 years after the last dose, and then give a booster dose every 5 years thereafter.  
| **Pneu-P-23**                 | - For those 2 years and older.  
                                - Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose.  
| **Hib**                       | - Immunization with an age-appropriate primary series should be completed for children less than 5 years old.  
                                - 1 dose Hib for people 5 years and older regardless of Hib immunization or Hib disease history.  
| **HB**                        | - For HIV infected persons, refer to SIM Appendix 7.4: High Dose Hepatitis B Immunization Algorithm.  
| **Var** Specialist consultation required.** | Refer to Appendix 7.2: Varicella Immunization Referral Form.  
| **MMR** Specialist consultation required.** | Refer to Appendix 7.3: MMR Immunization Referral Form.  
| **VarIg**                     | A symptomatic HIV-infected person, without either a history of chickenpox or demonstrable varicella antibody, who experiences a significant exposure to varicella or to zoster, should receive varicella-zoster immune globulin (VarIg) within 96 hours following contact.  
| **Ig**                        | HIV-infected children, regardless of immunization history, should receive immune globulin after a recognized exposure to measles. Ig may be considered if individual is a case contact of hepatitis A.  

\(^1\) For specific vaccine information, refer to SIM, Chapter 10, Biological Products.  
\(^2\) A high-risk child 12 months of age and older, or an adult who is cohort eligible for a Men-C-C, does not require Men-C-C vaccine when they are eligible to receive Men-C-ACYW-135 vaccine.
3.4 Transplant Candidate or Recipient – Islet Cell

- Refer to Appendix 7.9: Publicly Funded Immunization Schedule for Adult Solid Organ Pre-Transplant Candidates and Appendix 7.10: Publicly Funded Immunization Schedule for Adult Solid Organ Post-Transplant Recipients.

- For patients who receive their transplant outside of SK, consult with the jurisdictional transplant program coordinating things for the patient and to follow whatever schedule is requested even if their recommendations differ from Saskatchewan guidelines. The type of transplant, medical history, current medical condition, and immunosuppressive drugs are important factors when determining immunization regimens for post-transplant patients.

3.5 Transplant Candidate or Recipient – Solid Organ/Tissue

- Refer to Appendix 7.9: Publicly Funded Immunization Schedule for Adult Solid Organ Pre-Transplant Candidates and Appendix 7.10: Publicly Funded Immunization Schedule for Adult Solid Organ Post-Transplant Recipients.

- For patients who receive their transplant outside of SK, consult with the jurisdictional transplant program coordinating things for the patient and to follow whatever schedule is requested even if their recommendations differ from Saskatchewan guidelines. The type of transplant, medical history, current medical condition, and immunosuppressive drugs are important factors when determining immunization regimens for post-transplant patients.
3.6 Transplant Recipient – Haematopoietic Stem Cell Transplant (HSCT)

- Consult with the jurisdictional haematology/blood & bone marrow transplant program transplant physician for recommended immunizations. The type of transplant, medical history, current medical condition and immunosuppressive agents are important factors when determining immunization requirements for HSCT clients.
- Decisions about which vaccines to give will be made by the transplant team and the vaccines provided by the Ministry of Health. Public Health must administer the assigned immunization schedule provided by the transplant agency.
- Refer to Appendix 7.6: Publicly Funded Immunization Schedule for Adult Post-Hematopoietic Stem Cell Transplant Recipients (all types) for recommended schedule for SK residents.

Hematopoietic stem cell transplantation (HSCT) results in immunosuppression from:
- Hematopoietic ablative therapy preceding transplant;
- Medications used to prevent or treat graft – versus – host disease (GVHD); and
- In some cases, the disease process necessitating the transplantation.

HSCT generally involves the ablation of the bone marrow followed by reimplantation of the person’s own stem cells (autologous HSCT) or stem cells from a donor (allogeneic HSCT). Recipients of allogeneic grafts from donors who are not closely matched siblings are at substantially greater risk for GVHD, suboptimal graft function, and delayed capability for immune system memory.

Depending on the pre-ablation immune status of the client in autologous HSCT or on the immune status of the donor in allogeneic HSCT, there may be some immunity to vaccine-preventable diseases following transplantation. However, antibody levels to vaccine preventable diseases decline 1 - 4 years after HSCT if the recipient is not re-immunized, regardless of whether the transplant was autologous or allogeneic. In the case of allogeneic HSCT, if possible, complete all appropriate vaccines and reinforcement doses for the donor at least 14 days before the procedure.

All clients registered with a provincial HSCT programs should be provided with a letter recommending both the vaccines and schedule of administration required. MHO consultation is recommended prior to immunizing these individuals. Post-HSCT clients should receive all indicated vaccines regardless of immunization history because ablation of stem cells prior to the procedure will affect client’s post-transplant immunity. Immunization with inactivated vaccines is generally started 6 - 12 months post HSCT, except inactivated influenza vaccine, which can be administered 4-6 months post HSCT.

Live vaccines must not be administered until 24 months post HSCT. Specialist consultation is required prior to immunization with live vaccines. Refer to Appendix 7.2: Varicella Immunization Referral Form and Appendix 7.3: MMR Immunization Referral Form. Live bacterial vaccines (e.g., oral typhoid vaccine, BCG) are contraindicated.
3.7 Medical Treatment
Immunosuppression may result from or be implemented before the following (non-exhaustive) medical treatments:

- Long-term/high dose corticosteroids
- Cancer chemotherapies
- Radiation therapies
- Immunosuppressants (immunologic modulators, anti-rheumatic drugs (including tumour necrosis factor blockers), monoclonal antibody medications)
- Post-transplant – solid organ, islet cell or hematopoietic stem cell. For more information on transplant candidates and recipients refer to SIM chapter 7 sections 3.4, 3.5, and 3.6.

Individuals immunized appropriately before receiving chemotherapy or radiation therapy are thought to retain immune memory after treatment and re-immunization is not necessary.

Inactivated Vaccines
Although inactivated vaccines can be safely administered any time before, during or after immunosuppression, inactivated vaccines should be administered at least 14 days before initiation of immunosuppressive therapy to optimize immunogenicity. If immunization cannot be completed prior to initiation of immunosuppressive therapy, generally a period of at least 3 months should elapse between therapy cessation and the administration of inactivated vaccines. If the therapy cannot be stopped, inactivated vaccines should be given when the therapy is at its lowest.

Except for inactivated influenza vaccine, immunization during chemotherapy or radiation therapy should be avoided if possible because antibody response might be suboptimal. Patients vaccinated within 14 days before starting immunosuppressive therapy or while receiving immunosuppressive therapy should be considered unimmunized and should be revaccinated at least 3 months after their therapy is discontinued providing their immune competence has been restored (CDC (2011), https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm). A MHO referral is not required to re-immunize a client with inactivated vaccines according to above statement only.

The third dose of Pneu-C-13 vaccine that forecasts at 6 months of age is unnecessary for infants whose mothers took monoclonal antibody medications while pregnant.

Live Vaccines
Live vaccines are generally contraindicated during immunosuppressive therapy. Live vaccines should be administered at least 4 weeks before immunosuppressive therapy is started to reduce the risk of disease caused by the vaccine strain. An analysis of immunization risk versus benefit may be necessary if only low doses of therapy are required and there is significant risk of developing wild-type infection. In this case, consult with the individual’s specialist before immunization. If this cannot be done safely, delay immunization for at least 3 months after immunosuppressive therapy has stopped.

Refer to SIM Appendix 8.2 Potentially Immunosuppressive Biologic Agents for live vaccine contraindications for infants whose mothers took monoclonal antibody medications during pregnancy.
3.7A: Publicly Funded Vaccines ¹ - Medical Treatment

<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Requirements</th>
</tr>
</thead>
</table>
| All routine inactivated vaccines, including influenza | • Complete a Pneu-C-13 series for medically high-risk children. ²  
• 1 dose for Pneu-C-13 vaccine naïve individuals 5 years and older |
| HPV-9 | • 3-dose schedule: 0.5 mL IM at 0, 2, and 6 months for females and males aged 9 up to and including 26 years of age with the following risk factors (ineligible at 27th birthday):  
  - Immunocompromised – Acquired complement deficiency  
  - Immunocompromised – Congenital immunodeficiency  
  - Immunocompromised – HIV  
  - Immunocompromised – Related to Disease  
  - Immunocompromised – Treatment – Specify |
| Pneu-P-23 | • For those 2 years and older.  
• Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose. |
| Hib | • Immunization with an age-appropriate primary series should be completed for children less than 5 years old.  
• 1 dose Hib for people 5 years and older regardless of Hib immunization or Hib disease history. |
| Varicella | Specialist consultation required. Refer to Appendix 7.2: Varicella Immunization Referral Form. |
| MMR | Specialist consultation required. Refer to Appendix 7.3: MMR Immunization Referral Form. |

¹ For specific vaccine information, refer SIM, Chapter 10, Biological Products.
² The third dose of Pneu-C-13 vaccine that forecasts at 6 months of age in unnecessary for infants whose mothers took monoclonal antibody medications while pregnant.

3.7.1 High Dose Corticosteroid Therapy

Only oral high dose systemic steroids interfere with vaccine induced immune responses (e.g., consider persons receiving prednisone equivalent of ≥ 2 mg/kg/day or 20 mg/day if weight > 10 kg, for ≥ 14 days to be immune-suppressed). At least 1-3 months should elapse between high dose corticosteroid therapy administered for more than 2 weeks and administration of both inactivated vaccine (to ensure immunogenicity) and live vaccine (to reduce the risk of dissemination).

The following types of corticosteroid therapy will not cause immunosuppression and live vaccines can be administered to persons receiving such therapy:  
• prednisone equivalent of less than 2 mg/kg/day or less than 20 mg/day if weight > 10 kg;  
• less than 14 days;  
• prescribed as alternate day treatment or rapidly tapering with short-acting preparations;  
• administered topically (skin, eyes, respiratory) or by intra-articular, intraocular, bursal, aerosol, rectal or tendon injection; or  
• Children with adrenogenital syndrome and those receiving physiologic replacement doses (< 2 mg/kg of prednisone per day) of glucocorticoids should receive all routine immunizations on schedule.
4.0 POST-EXPOSURE

4.1 Infant Born to HBsAg Positive Mother or High Risk for HB ≥ 2000g

4.2 Infant Born to HBsAg Positive Mother or High Risk for HB < 2000g

Infants born to mothers who are HBsAg positive during pregnancy have a risk of contracting HB infection. Without intervention, this risk is estimated to be 90% if the mother is HBsAg positive and 5-20% if the mother is HBsAg negative. Infants who contract HB infection have a 90-95% risk of developing chronic HB infection potentially leading to cirrhosis and hepatocellular carcinoma. All women should be screened for the presence of HBsAg during every pregnancy. If she is HBsAg is positive or has an unknown status but she is considered to be at high risk for HB infection (e.g. intravenous drug use, sex trade worker), protocols are in place to ensure that the infant is immunized with HBlg and HB vaccine as soon as possible after delivery.

When HBlg and HB vaccine is provided within 12 hours after birth, the risk of HB infection in the infant is reduced by 90% (CIG). Ideally, HBlg should be given immediately after birth, along with one dose of HB vaccine. Give HB vaccine and HBlg at the same time using separate syringes and separate limbs. The HB vaccine series for these infants should be completed at 6 months of age (refer to chart below). It is recommended that these infants be tested for HBsAg and anti-HBs when they are at least 9 months old, and at least 1 month but no more than 4 months after their HB series is complete (CIG). Prior to discharge, Appendix 7.5: Prophylactic Record Referral Form for Infants at High Risk of Hepatitis B should be completed and referred to the appropriate health care practitioners.

4.2.1 Hepatitis B Infant Immunoprophylaxis Protocol 1, 2
(Whose Mothers are HBsAg positive or are at High Risk of HB Infection and Their Status is Unknown and STAT Order Testing Cannot be Obtained Within 12 Hours After Delivery).

<table>
<thead>
<tr>
<th>Birth weight</th>
<th>Give &lt; 12 hours after birth</th>
<th>Give at 1 month of age</th>
<th>Give at 2 months of age</th>
<th>Give at 6 months of age ³</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2000g</td>
<td>HBlg 0.5 mL IM</td>
<td>2nd HB vaccine</td>
<td>N/A</td>
<td>3rd HB vaccine</td>
</tr>
<tr>
<td></td>
<td>1st HB vaccine 0.5 mL IM</td>
<td>0.5 mL IM</td>
<td></td>
<td>0.5 mL IM</td>
</tr>
<tr>
<td></td>
<td>Give at different sites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 2000g</td>
<td>HBlg 0.5 mL IM</td>
<td>2nd HB vaccine</td>
<td>3rd HB vaccine</td>
<td>4th HB vaccine</td>
</tr>
<tr>
<td></td>
<td>1st HB vaccine 0.5 mL IM</td>
<td>0.5 mL IM</td>
<td>0.5 mL IM</td>
<td>0.5 mL IM</td>
</tr>
<tr>
<td></td>
<td>Give at different sites</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
2 Refer to SIM, Chapter 5, Section 2.1, Minimum Intervals for Specific Vaccine Series for more information.
3 Child must be 24 weeks of age or older to receive this dose.

5.0 SPECIAL POPULATION

5.1 Men who have Sex with Men

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA¹</td>
<td>2 doses given 6 -12 months apart</td>
</tr>
<tr>
<td>HB¹</td>
<td>Age-appropriate series</td>
</tr>
<tr>
<td>Mpox¹</td>
<td>Refer to SIM, Chapter 10, Biological Products.</td>
</tr>
</tbody>
</table>

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.
5.2 Pregnancy

"Benefits of vaccinating pregnant women usually outweigh potential risks when the likelihood of disease exposure is high, when infection would pose a risk to the mother or fetus, and when the vaccine is unlikely to cause harm". (Plotkin, Orenstein, & Offit, 2008, p. 99).

5.2.1 Pregnancy

Pregnancy is a time when a healthy woman may have more contact with the medical system than at any other time. All pregnant women should be evaluated for immunity to rubella and varicella and be tested for the presence of HBsAg at the first prenatal visit. It is an opportune time to assess her immunization status and administer any appropriate vaccines that will provide protection for both her and her child against vaccine-preventable diseases. There are no data to indicate that any of the currently approved vaccines are teratogenic or embryotoxic, result in specific adverse pregnancy outcomes, or result in inadequate antibody responses when given to pregnant women.

5.2.1.1 Inactivated Vaccines

Inactivated vaccines may safely be given to pregnant women when indicated (e.g., seasonal influenza vaccines, Td/Tdap for wound management).

5.2.1.2 Live Vaccines

MMR, Var, and LAIV vaccines are indicated only for pre-conception and post-partum (including breastfeeding) women. Live, attenuated viral and live bacterial vaccines pose a theoretical risk to the developing fetus and are generally contraindicated during pregnancy. There are occasions when administration of a live vaccine during pregnancy may be considered (e.g., travel to a yellow fever endemic region), when the risk of disease outweighs any risk from receiving the vaccine.

Suggested guidelines before immunizing females of childbearing age with live vaccines include:

• Asking women if they are pregnant or might become pregnant in the next 1 month;
• Defer immunizing women who state they are pregnant or are planning a pregnancy in the next month;
• Explaining the theoretical risk to the fetus if live vaccines are given during pregnancy;
• Advise women to avoid becoming pregnant for 1 month after receiving a live vaccine;
• If a woman is pregnant and inadvertently immunized or becomes pregnant within 1 month of receiving a live vaccine, she should be counselled about the theoretical risk to the fetus;
• Live vaccine manufacturers monitor such incidents and can be contact as follows:
  o GlaxoSmithKline (Varilrix, Priorix) medical information line: 1-800-387-7374.
  o Merck Frosst (Varivax III, MMR II) medical services line: 1-800-567-2594.
• Immunization with live vaccines during pregnancy should not be a reason to terminate a pregnancy.
5.2.A: Publicly Funded Vaccines ¹ - Pregnancy

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Requirements</th>
</tr>
</thead>
</table>
| Tdap          | • Offered Tdap at or after 27 weeks gestation (CIG, NACI).  
• If Tdap is administered to a pregnant woman before 27 weeks gestation, she does not need another Tdap after 27 weeks gestation or post-delivery.  
• A Tdap vaccine should be routinely offered to all pregnant women in every pregnancy, irrespective of their immunization history. One dose of Tdap vaccine should ideally be provided between 27 and 32 weeks of gestation. Earlier immunization between 13 and 26 weeks of gestation may also be considered in some situations (e.g., in case of an increased risk of preterm delivery or travel) to allow for longer placental exposure to higher antibody levels and maximization of antibody transfer. While it is preferable that immunization is administered at least 4 weeks before birth to allow optimal transfer of antibodies and direct protection of the infant against pertussis, it should be considered until the end of pregnancy as it has the potential to provide partial protection.  
• Women who did not receive Tdap during their current pregnancy do not require Tdap post-delivery, unless they require a routine dose. |
| Inactivated influenza | Any trimester during seasonal influenza campaigns.                                                                                   |
| HB            | As indicated for risk group.                                                                                                       |
| HA            | As indicated for risk group.                                                                                                       |
| Pneu-P-23     | As indicated for high risk individuals.                                                                                             |
| Men-C-C or Men-C-ACYW-135 | In an outbreak situation as per the Saskatchewan Communicable Disease Control manual.                                              |
| MMR ²         | Contraindicated during pregnancy.                                                                                                 |
| Var ³         | Contraindicated during pregnancy.                                                                                                 |

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

² MMR vaccine is recommended post-partum or preconception for susceptible women. Refer to Appendix 5.2: Publicly Funded MMR Vaccine Eligibility.

³ Refer to Appendix 5.4 Publicly Funded Varicella Immunization Eligibility and Panorama Directives. Women of childbearing age who do not have ANY of the following are considered susceptible to varicella (adapted from the Canadian Immunization Guide, 2012):

- Serological evidence of V2V IgG antibodies; or
- Documented evidence of immunization with two doses of a varicella-containing vaccine.
- Advise women who are immunized to avoid pregnancy for one month following immunization.

According to the CIG, (2012 Evergreen Ed., accessible at http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-10-eng.php#meas) the first varicella vaccine dose should be given in the immediate post-partum period, before discharge from hospital unless they have received Rh immune globulin [RhIg]. To optimize response to vaccine, varicella-susceptible women who receive RhIg in the peri-partum period should generally wait 3 months before being vaccinated with varicella vaccine. The risk of lowered vaccine efficacy needs to be weighed against the need for protection. However, if there is a risk of exposure to varicella, a risk of recurrent pregnancy in the 3-month post-partum period, or a risk that vaccines may not be given later, monovalent varicella vaccines may be given prior to discharge. In that context, serologic testing for varicella should be done 3 months later and non-immune women should be revaccinated with two Var doses given at appropriate intervals from the initial post-partum dose (NOTE: they may receive 3 vaccine doses in total). In the event that a post-partum woman receives varicella vaccine prior to receiving RhIg within 72 hours post-delivery, serologic testing for varicella should be done 3 months later and the woman revaccinated if non-immune with two Var doses given at appropriate intervals from the initial post-partum dose (NOTE: they may receive 3 vaccine doses in total).
5.2.1.3 Passive Immunizing Agents and Blood Products during Pregnancy
Pregnant women may receive immune globulin preparations (e.g., RabIg, VarIg) and blood products when indicated. No known risk exists for the fetus from passive immunization of pregnant women with any immunoglobulin preparations.

Susceptible women that are eligible to receive MMR or Var vaccines should be immunized as soon as possible post-partum. If they have received any immunoglobulin or blood products during pregnancy or the post-partum period, specific time intervals must be adhered to before administering live viral vaccines. Refer to SIM, Chapter 5, Section 3.5.1, Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus for further information on recommended timing of vaccines and biological and immunoglobulin products. Refer to the footnotes in SIM Chapter 7 section 2.3.1A for specific vaccine guidance. If an immune globulin is given more than 14 days after MMR or varicella vaccine, neither vaccine needs to be repeated.

5.2.2 Breastfeeding
• Breastfeeding mothers should receive all recommended immunizations according to schedule.
• Inactivated and live vaccines administered to breastfeeding women do not affect the safety of breastfeeding for women and infants, or maternal immune responses.
  • Exceptions:
    o Yellow fever (YF) vaccine should be avoided in breastfeeding women because of a risk of transmission of the virus in breastmilk. If travel to an endemic area is required, then immunizing breastfeeding women with YF vaccine is a lesser risk than that of acquiring the disease.
    o Although rubella vaccine virus might be excreted in human milk, rarely does the virus infect the infant. If infection does occur in the infant, it is well tolerated because the rubella virus is attenuated.
6.0 OCCUPATION

Best Practice Guidelines

The following guidelines constitute advice on best practices to facilitate/ensure consistent procedures and policies regarding employee immunizations. It is the responsibility of every employer to:

1. Assess the immunization/immunity status of each worker at the time of initial employment as per Section 6.5, Publicly Funded Vaccines - Healthcare - RHA/SCA/CC/FNJ and Students as a guideline.

2. Obtain an immunization history, including documentation of the vaccines and doses received, and dates of administration.

3. Offer or refer for immunizations at the earliest opportunity to employees who do not have documented evidence of immunization or adequate immunity.

4. Maintain records of all immunizations provided, serologic, and tuberculin skin test results. The employee should also be provided with a copy of these records.

5. Institute an immunization recall system to ensure immunization series are completed.

Healthcare Worker Information

HCWs have the potential for exposure to patients and/or to infectious materials (e.g., body substances, contaminated medical supplies and equipment, contaminated environmental surfaces and air). HCWs are at risk of exposure to communicable diseases (diagnosed or undiagnosed) because of their contact with patients or material from infectious patients. The level of exposure risk and/or transmission of pathogens and diseases should be considered in conjunction with the specific vaccines recommended, as exposure circumstances may vary in facilities. A HCW may have varying levels of risk if they change positions or work environments, therefore assessment of their potential risk should be ongoing. Should a HCW become exposed, infected, or knowingly have an increased risk of exposure (e.g. needle stick incident) their immunization schedule would be determined by the circumstances involved. Maintenance of HCW immunity against vaccine-preventable diseases is an integral part of a health care facility’s occupational health program. Optimal usage of immunizations among HCWs will not only safeguard the health of staff members but may also protect patients from becoming infected by HCWs.

HCWs for which immunizations are contraindicated should have a medical exemption issued by their treating medical physician or nurse practitioner and reviewed by the facility Occupational Health and Safety Consultant and/or regional Medical Health Officer for validation of true contraindications. Such exemptions should be reviewed as appropriate (e.g., during influenza disease outbreaks).

HCWs who received HB vaccine in years prior to enrolment as a student in a healthcare profession or years prior to employment as a health care worker may be tested to determine protective status for hepatitis B. If the anti-HBs titre is < 10 IU/L (but detectable), provide one dose of vaccine and retest 4 weeks after this dose. If level is ≥ 10 following this dose, no further vaccine is required. When anti-HBs is < 10 IU/L after this one dose, complete the second vaccine series and retest 4 weeks after the last dose. Status as a non-responder must be documented on the employee health record.

6.1 Child Care

Maintenance of an up-to-date immunization status is vital to protect the health of both childcare workers and the children in their care. Persons who will be providing direct childcare should have written proof of vaccinations previously received. Employers are responsible to ensure that their employees are fully immunized. Refer to SIM, Chapter 5, Immunization Schedules for further information.
6.2 **Health Care Worker – Eligible for Publicly Funded Vaccines**

The Saskatchewan Ministry of Health defines a AHA/SHA/SCA/CC/FNJ HCW as a clinical and/or non-clinical individual employed (paid) by AHA/SHA/SCA/CC/FNJ and their respective affiliates, and includes individuals who have been appointed as Practitioner Staff (e.g., midwives). This includes special care and long-term care facilities.

An HCW who is not employed by AHA/SHA/SCA/CC/FNJ and their respective affiliates is eligible for routine adult vaccines as noted in Chapter 5, *Immunization Schedules*.

**6.2.1 Students of Health Care Professions – Eligible for Publicly Funded Vaccines**

Post-secondary students of health care professions are eligible to receive the same vaccines as noted in section 6.2, so refer to section 6.3 *Health Care Worker – Eligible for Publicly Funded Vaccines* and to Publicly Funded Hepatitis B Vaccine Eligibility for Students of Health Care Professions in Chapter 10.
### 6.3 Health Care Worker – Eligible for Publicly Funded Vaccines
Refer to Chapter 10, Biological Products for specific vaccine information.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Immunity Criteria</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tdap</td>
<td>• Documentation of a 3-4 dose tetanus primary series, with last dose given &lt; 10 years ago.</td>
<td>• Tdap recommended every 10 years after primary series and is not recommended to administer it sooner regardless of employer or educational institution.</td>
</tr>
<tr>
<td>IPV</td>
<td>• Documentation of a 3-dose primary series given by any route with at least one dose received at 4 years of age or older.</td>
<td>• Reinforcement (booster) doses are not publicly funded or recommended after a primary series for HCWs.</td>
</tr>
<tr>
<td>HB</td>
<td>• Documentation of an age-appropriate 2 or 3 dose HB series and adequate serologic antibodies at least 4 weeks post immunization; or • Serological evidence of previous HB infection (anti-HBs+ &amp; anti-HBc+; or HBsAg+ &amp; Anti HBc IgM).</td>
<td>• If titres are &lt; 10 IU/L any time after the completion of a primary HB series, refer to Chapter 7 Section 6.0 Occupation for recommendations. • Non-responders that have completed two HB immunization series are unlikely to benefit from further HB immunization and are considered indefinitely susceptible to HB virus. They must receive two doses of HBIG one month apart if exposed.</td>
</tr>
<tr>
<td>Influenza</td>
<td>None.</td>
<td>• Annual immunization.</td>
</tr>
<tr>
<td>Varicella</td>
<td>• Documentation of two doses of a varicella-containing vaccine; or • Serological evidence of VZV IgG antibodies.</td>
<td>• Contraindicated during pregnancy. Counsel women to avoid pregnancy for 1 month post-immunization.</td>
</tr>
<tr>
<td>Measles</td>
<td>• Documentation of two doses of a measles-containing vaccine; or • Serological evidence of measles IgG antibodies.</td>
<td>• MMR vaccine is publicly funded for HCWs. Refer to Chapter 5, Appendix 5.2: Publicly Funded MMR Vaccine Eligibility to assess MMR dose eligibility. • Contraindicated during pregnancy. Counsel women to avoid pregnancy for 1 month post-immunization.</td>
</tr>
<tr>
<td>Mumps</td>
<td>• Documentation of two doses of a mumps-containing vaccine; or • Serological evidence of mumps IgG antibodies.</td>
<td>• MMR vaccine is publicly funded for HCWs. Refer to Chapter 5, Appendix 5.2: Publicly Funded MMR Vaccine Eligibility to assess MMR dose eligibility. • Contraindicated during pregnancy. Counsel women to avoid pregnancy for 1 month post-immunization.</td>
</tr>
<tr>
<td>Rubella</td>
<td>• Documentation of one dose of a rubella-containing vaccine (NOTE: Although a second dose of rubella is not considered necessary for immunity, it is not harmful and may benefit the 1% to 5% of people who do not respond to primary immunization (CIG)); or • Serological evidence of rubella IgG antibodies.</td>
<td>• MMR vaccine is publicly funded for HCWs. Refer to Chapter 5, Appendix 5.2: Publicly Funded MMR Vaccine Eligibility to assess MMR dose eligibility. • Contraindicated during pregnancy. Counsel women to avoid pregnancy for 1 month post-immunization.</td>
</tr>
</tbody>
</table>
7.0 OTHER POPULATIONS

7.1 Premature Birth
A premature infant whose health is assessed by their physician to be clinically satisfactory should be immunized at the same chronological age as full-term infants, according to the routine immunization schedule. Antibody response to immunization is generally a function of chronological age rather than maturity and vaccine efficacy is high in premature infants. Low rates of adverse events are similar to those of full-term infants.

Premature infants have lower maternal antibodies titres and shorter duration of maternal antibody protection. The severity of vaccine preventable illnesses may be greater in preterm and low birth weight infants. Preterm birth is associated with increased risk of complications and death from pertussis in infancy. Preterm infants are at greater risk of developing complications from influenza. All preterm infants 6 months of age and older and their household contacts should be immunized yearly with (publicly funded) influenza vaccine.

Premature infants and other children at risk of contracting respiratory syncytial virus (RSV) may be eligible to receive palivizumab (SYNAGIS®). SYNAGIS® is a passive immunization product, but does not interfere with the immune response of vaccines (refer to SIM, Chapter 5, Immunization Schedules, Section 3.5, Spacing of Live Vaccines, Blood Products and Immune Globulin Preparations). A provincial RSV program exists to coordinate this service outside of public health https://momsandkidssask.saskhealthauthority.ca/infant-child-health/specialty-care/respiratory-syncytial-virus-program

Publicly Funded Vaccines ¹ — Premature Birth

| All routine vaccines | Immunize according to routine schedule as appropriate for age |

¹ For specific vaccine information, refer to SIM, Chapter 10, Biological Products.

7.2 Individuals Recently New to Canada
Immunization of children and adults, including foreign students, who have newly arrived in Canada is challenging because:

- Documented Immunization records may not exist or be suspect.
- Refer to Appendix 7.8 Publicly Funded Immigrant and Refugee Immunization and Serology Recommendations when assessing individuals recently new to Canada.
- For specific vaccine eligibility information, refer to SIM, Chapter 5 Immunization Schedules. All immunization recommendations in chapter 5 are for routine immunizations. Individuals may be eligible for additional vaccines based on health conditions or other risk factors.
- For specific vaccine information, refer to SIM Chapter 10 Biological Products.
- Records that do exist may be difficult to interpret because of language barriers. Refer to Appendix 14.4 Immigrant Immunization Resources for translation aids.
- Immunization schedules and products may differ from those used in Canada.
- Translation of foreign terms for immunization products can be found at http://www.cdc.gov/vaccine/pubs/pinkbook/downloads/appendices/B/foreign-products-tables.pdf
- Information on vaccination schedules in other countries can be found at the WHO Immunization Data https://immunizationdata.who.int/listing.html?topic=vaccine-schedule&location=
Only written documentation of immunizations should be considered valid evidence of prior immunization history. The potency of vaccines administered in other countries can be generally assumed adequate. Immunizations received outside Canada can be considered valid if the written documentation indicates the vaccine antigen types, administration dates, number of doses, intervals between doses, and the age of the client at time of immunization are comparable with the current Saskatchewan recommendations. Re-immunize any child immunized outside of Canada, if any question exists about whether vaccines were administered or were immunogenic. In some situations, use of serologic testing may be useful in determining which vaccines are needed. If a child experiences a significant local reaction after one dose of tetanus and diphtheria-containing vaccine, consider serologic testing for antibodies to diphtheria and tetanus toxoids.

Internationally adopted children from orphanages may differ from refugee children in terms of their access to medical care and treatment before arrival in Canada. Immunization records for certain children, especially children from orphanages, may not be accurate (e.g., MMR may be recorded but the actual product administered may be missing one of the antigens). Refugee children may have resided in refugee processing camps for months before resettlement in Canada and may have had access to medical care and immunization in the camp. The following vaccines are in limited use in the developing world and, therefore, individuals from such areas are unlikely to have received them.

- Meningococcal conjugate
- Pneumococcal conjugate
- Hib
- HPV
- Hepatitis B
- Varicella
- Mumps and rubella (measles vaccine alone is often given)

The epidemiology of different diseases varies in other countries:

- Compared with temperate climates, in the tropics a higher proportion of varicella disease occurs in adults, meaning that children, adolescents and young adults from those areas are more likely to be susceptible to varicella.
- Hepatitis A immunity is more common in individuals from endemic countries and regions.
- Individuals born in developing countries are more likely to be hepatitis B carriers, necessitating the need for assessment and immunization of their sexual and household contacts.

Ask the following questions when assessing the immunization status of an individual who is new to Canada:

- What country has the individual come from or lastly resided in?
- Were they in an orphanage or refugee camp?
- When did they arrive in Canada?
- Which immunizations were given prior to arrival and when?
- Were the immunizations comparable to Canadian recommendations, particularly:
  - Vaccine type;
  - Dates of administration;
  - Numbers of doses;
  - Intervals between doses; and
  - Age of client at time of immunization.
• What diseases were endemic in the country of previous residence?
  o If a client assessment is done, the following tests are particularly relevant in determining
    the need for some vaccines or contraindications to vaccination:
• Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B
  core antibody (anti-HBc): To identify current or chronic infection, past resolved infection, or
  evidence of immunization. Should any member of the family test positive for HBsAg, assess
  and immunize all susceptible sexual and household contacts.
• Hepatitis C antibody: If anti-HCV is positive in children < 18 months (may be due to circulating
  maternal antibodies), order hepatitis C PCR. Offer hepatitis A and B vaccines to individuals
  with hepatitis C infection.
• Human immunodeficiency virus (HIV): If individual is from a country with high rates of HIV and
  HIV status is unknown, testing should be encouraged. Routine HIV testing is done during the
  immigration medical examination for everyone > 15 years of age and certain children (those
  who received blood products, those whose mother was known to be HIV positive). If anti-HIV
  is positive in children 18 months or younger (may be due to circulating maternal antibodies),
  order HIV PCR.
• In the context of a complete clinical assessment in which no signs or symptoms consistent with
  advanced HIV/AIDS are identified, immunization with live vaccines may proceed when HIV
  tests are not yet available. Live vaccines are contraindicated for individuals with advanced HIV
  infection. Refer to Chapter 7, Section 1.0, Immunocompromised Individuals.
• Families new to Canada may return to their country of origin to visit friends and relatives or
  may receive visitors from their country of origin. Encourage such families to visit a travel
  health professional for consultation and immunization with appropriate vaccines, particularly
  HA and HB vaccines. Refer to SIM Chapter 10, Hepatitis B Vaccine – Immigrant Populations
  Ineligibility List which applies to children and adults.

### 7.3 Unknown or Uncertain Immunization Status/Inadequate Immunization Records

Refer to Chapter 5, Section 4.1 Unknown or Uncertain Immunization Status for Canadians, foreign-
born adult, and child immunization directives.
7.4 Travelers
Generally, vaccines for travellers are not publicly funded but there are some exceptions. Refer to SIM Chapter 5 Appendix 5.2 Publicly Funded MMR Vaccine Eligibility for parameters. Tetanus-containing vaccines for reinforcement are also publicly funded. Booster doses of IPV are not publicly funded.

Advise individuals considering international travel to make an appointment for a full consultation with a travel health provider. Refer clients to the following websites for travel health information:

- Public Health Agency of Canada - Travel Health section of the web site: available at http://www.travelhealth.gc.ca
REFERENCES


Centres for Disease Control and Prevention. (2010). Updated Recommendations for Use of Meningococcal Conjugate Vaccines – Advisory Committee on Immunization Practices. MMWR, 60(03). Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm?s_cid=mm6003a3_e


9.0 APPENDICES
Appendix 7.1: Publicly Funded Vaccine Recommendations for Specific Populations by Panorama Risk Factor Category

- Risk factors names are exactly worded from Panorama Immunization Module.
- Refer to the specific immune-suppressing conditions in SIM [Chapter 7, Special Populations] and specific vaccines in SIM [Chapter 10, Biological Products].
- NOTE: Not all agents forecast and/or validate for all risk factors.

<table>
<thead>
<tr>
<th>CHRONIC MEDICAL CONDITION (non-exhaustive examples)</th>
<th>Hib</th>
<th>HA</th>
<th>HB</th>
<th>MMR</th>
<th>Men-ACYW-135</th>
<th>Men-B4C</th>
<th>Pneu-C-13</th>
<th>Pneu-P-23</th>
<th>Var</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asplenia (congenital, acquired, functional) - congenital asplenia/hyposplenia; heterotaxy syndrome with asplenia/ polyasplenia; surgical splenectomy because of trauma, tumour, or as treatment for disease (e.g., idiopathic thrombocytopenic purpura, thalassemia major, spherocytosis); polyasplenia; hemoglobinopathies</td>
<td>•9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleeding disorders - haemophilia; thrombocytopenia; von Willebrand’s disease; Individuals who receive repeated infusions of blood or blood products or plasma-derived replacement clotting factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disease - coronary artery disease; cardiomyopathy; hypertensive heart disease; heart failure; dysrhythmias; cardiomegaly; myocarditis; valvular disease; cerebrovascular disease; congenital heart disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>CSF disorder - hydrocephalus; impaired cerebrospinal fluid disorder; lymphatic transport; surgical shunts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Cochlear implant – candidate or recipient</td>
<td>•9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cystic fibrosis - aka mucoviscidosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Diabetes mellitus - type 1 (IDDM); type 2 (NIDDM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Liver disease – alcoholism; alcoholic liver disease; fatty liver disease; cirrhosis; primary biliary cirrhosis; Budd–Chiari syndrome; primary sclerosing cholangitis; Hemochromatosis; Wilson’s disease; transthyretin-related hereditary amyloidosis; Gilbert’s syndrome; Biliary atresia; Alpha-1 antitrypsin deficiency; Alagille syndrome; progressive familial intrahepatic cholestasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Liver disease – HB (infection)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Liver disease – HC (infection)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Lung disease - asthma ONLY if on high dose oral corticosteroid therapy; bronchopulmonary dysplasia; cystic fibrosis; chronic obstructive pulmonary disorder; pleural mesothelioma; pulmonary tuberculosis; pulmonary arterial hypertension; pulmonary edema; pulmonary hematoma; congenital cystic adenomatoid malformation; restrictive lung disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Malignancies / Cancer – current cancers of any organ/body system</td>
<td>•9</td>
<td>C6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological conditions that impede the clearance of respiratory/oral secretions - transient ischemic attacks; cerebrovascular accidents; cerebral palsy; spina bifida; seizure disorders; acute demyelinating encephalomyelitis; transverse myelitis; Guillain-Barre syndrome; multiple sclerosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Renal disease - nephrotic syndrome; predialysis; peritoneal dialysis; hemodialysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2A</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>
### IMMUNOCOMPROMISED

<table>
<thead>
<tr>
<th>Condition</th>
<th>Hib</th>
<th>HA</th>
<th>HB</th>
<th>HPV-9</th>
<th>Men-C-ACYW-135</th>
<th>Men-B4C</th>
<th>Pneu-C-13</th>
<th>Pneu-P-23</th>
<th>MMR</th>
<th>Var</th>
<th>Rot-5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquired Complement Deficiency - treatment with Solaris® (e.g., terminal complement inhibitor eculizumab)</td>
<td>6</td>
<td>9</td>
<td>5</td>
<td>1, 12</td>
<td>10</td>
<td>2C</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td>Congenital Immunodeficiency - B cell deficiency; T-cell defects; complement component deficiency (C5-C9, properdin, factor H, factor D); phagocytic and neutrophil disorders</td>
<td>6</td>
<td>3</td>
<td>5</td>
<td>1, 12</td>
<td>10</td>
<td>2C</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td>HIV</td>
<td>6</td>
<td>3</td>
<td>5</td>
<td>1, 4</td>
<td>4</td>
<td>8</td>
<td>10</td>
<td>6</td>
<td>6</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>Related to Disease – myelodysplasia; collagen vascular disease</td>
<td>6</td>
<td>3</td>
<td>5</td>
<td>2A</td>
<td>10</td>
<td>2C</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
<td>C</td>
</tr>
</tbody>
</table>

#### Transplant Candidate or Recipient - Islet Cell

Refer to SIM Ch. 7 Sections 3.4, 3.5 and 3.7.

Administer transplant agency recommended vaccines as scheduled. Contact the transplant agency directly if client vaccine eligibility concerns arise (e.g., Hib not noted on agency protocol).

#### Transplant Candidate or Recipient - Solid Organ/Tissue - all solid organ/tissue transplant candidates and recipients

#### Transplant Recipient - HSCT

*Treatment - Additional info - chemotherapy and radiation therapies; currently taking immunosuppressants (e.g., for inflammatory bowel disease; systemic lupus erythematosis; rheumatoid arthritis (e.g., immune modulators such as anti-rheumatics drugs); long-term corticosteroids; infant’s mother took monoclonal antibodies during pregnancy*

<table>
<thead>
<tr>
<th>POST-EXPOSURE</th>
<th>HB</th>
<th>HBlg</th>
<th>Rab</th>
<th>Rablg</th>
<th>T</th>
<th>Tlg</th>
<th>Varlg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and Body Fluids - percutaneous or mucosal exposure to: blood or body fluid (e.g., needle stick injury, human bite); or to HBsAg positive source; sexual assault</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infant Born to HBsAg+ Mom or High Risk for HB – any birth weight</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabies - individual with animal bite/exposure with risk of rabies (with MHO approval)</td>
<td></td>
<td></td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus-prone wound - Tlg required - contraindication to a tetanus toxoid-containing vaccine; significant immune deficiency state; unimmunized individual with a tetanus-prone wound. Refer to Ch. 5 Section 3.7 <em>Tetanus Prophylaxis in Wound Management</em>.</td>
<td></td>
<td></td>
<td>•</td>
<td>13</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella – susceptible individuals at increased risk of severe varicella disease</td>
<td></td>
<td></td>
<td></td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### OCCUPATION

<table>
<thead>
<tr>
<th>Occupation</th>
<th>HB</th>
<th>MMR</th>
<th>VAR</th>
<th>IPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child Care - Child care employees; Post-secondary child care students</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Care Worker – eligible for publicly funded vaccines</td>
<td>Refer to SIM Ch. 5</td>
<td>Refer to SIM Ch. 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPECIAL POPULATION</td>
<td>H</td>
<td>H</td>
<td>HBig</td>
<td>Pneu-C-13</td>
</tr>
<tr>
<td>---------------------</td>
<td>---</td>
<td>---</td>
<td>------</td>
<td>-----------</td>
</tr>
<tr>
<td>Caregivers of Newborns – adult caregivers of infants younger than 6 months old (e.g. fathers, grandparents, childcare providers, etc.).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children of Immigrants – HB - children of immigrants from regions of intermediate or high HB prevalence. This includes all children born before the family’s arrival in Canada and all children born after the family’s arrival in Canada.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A Program - Targeted Community - people born since Jan. 1/82 who live in the Athabasca Health Authority; off reserves in Northern Saskatchewan (previous Mamawetan Churchill River and Keewatin Yatté health regions excluding Creighton, Air Ronge and La Ronge); or on reserves anywhere in SK regardless of where they access immunization services.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Household member of an immunocompromised person</td>
<td>Refer to SIM Chapter 5 Section 1.0 Routine Schedules</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTC facility - adults and children whom are residents of special care homes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-responder - HB - non-responder to a second valid series of hepatitis B vaccine (i.e. a 2-series non-responder).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-responder - Additional information - specify disease after valid appropriate series complete e.g., varicella, measles, mumps, rubella, HA, first HB series, etc.</td>
<td>Specify disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substance Use – Illicit non-injection drug use - use by ingestion, snorting, smoking, inhalation etc., excluding injection. Cannabis products excluded.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substance Use – Injection drug use - use by injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potential Exposure – HA - sexual partners and household contacts of individuals who use illicit drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potential Exposure – HB - males and females with multiple sexual partners; sexual partners and household contacts of individuals who use illicit drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy – every pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resident – Group Home (e.g., residents of institutions for the developmentally challenged)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resident – Provincial Correctional Facility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual Behaviour - MSM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella - Woman Childbearing Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TRAVEL</th>
<th>MMR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publicly funded - Refer to SIM Chapter 5 Appendix 5.2.</td>
<td></td>
</tr>
<tr>
<td>Sales Program</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TREATMENT</th>
<th>BAT</th>
<th>BabyBlg</th>
<th>DAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botulism - Greater than or equal to one year of age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Botulism - Less than one year of age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### CONTACT
(Refer to the Saskatchewan Communicable Disease and Control Manual for all cases)

<table>
<thead>
<tr>
<th>CONTACT</th>
<th>HA</th>
<th>Ig</th>
<th>HB</th>
<th>HBig</th>
<th>Men-B4C</th>
<th>Men-C-C</th>
<th>Men-C-ACYWW-135</th>
<th>MMR</th>
<th>ap/aP</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA - contact to an acute lab confirmed HA case</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HB - sexual contact of an acute or chronic HB case; household and close contacts of an acute or chronic HB case</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMD Case: Serogroup A, Y, or W-135 - contact to a lab confirmed case of invasive meningococcal disease serogroup A, Y, or W-135 when immunoprophylaxis is recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMD case: Serogroup B - contact to a lab confirmed case of invasive meningococcal disease serogroup B when immunoprophylaxis is recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMD case: Serogroup C - contact to a lab confirmed case of invasive meningococcal disease serogroup C when immunoprophylaxis is recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles - contact to lab confirmed case of measles when immunoprophylaxis with measles-containing vaccine or Ig is recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pertussis outbreak: Defined community - use only for an outbreak declared in a defined community by the MHO, and as directed by the Ministry of Health. This does not apply to individual cases.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C – Consultation required as may be contraindicated.

1 A high-risk child 1 year age and older, or a high risk adult who is cohort eligible for a Men-C-C should receive Men-C-ACYW-135. If younger, give Men-C-ACYW-135 as per infant schedules; don’t wait/delay giving the series until the person is 1 year old.

2 A 1 dose for Pneu-C-13 naïve persons 5 years up to and including 17 years old

2A The third dose of Pneu-C-13 vaccine that forecasts at 6 months of age in unnecessary for infants whose mothers took monoclonal antibody medications while pregnant.

2C 1 dose for Pneu-C-13 naïve persons 5 years and older.

3 Refer to Appendix 7.4: High Dose Hepatitis B Immunization Algorithm appropriate dosages and products appropriate for client’s age.

4 Children up to and including 17 years of age only.

5 3-dose series; must receive first public funded dose before age 27 to continue publicly funded series.

6 Medical consultations are required; refer to Appendix 7.2: Varicella Immunization Referral Form and Appendix 7.3 MMR Immunization Referral Form.

7 Transplant agency determines immunizations.

8 1 dose of Pneu-C-13 naïve persons all ages.

9 People 5 years and older with medical conditions noted in SIM Chapter 10, Biological Products regardless of Hib immunization or Hib disease history.

10 Eligible for booster 5 years after first dose except for alcoholism.

11 If received less than 3 tetanus vaccine doses in the past.

12 Lifetime Men-C-ACYW-135 boosters – see SIM Chapter 10, Biological Products for intervals based on age that first dose was administered.

13 Use appropriate tetanus vaccine formulations based on age and antigen requirements.

14 Tdap if adult has not received one pertussis dose since 18 years old.

15 Only for residents of institutions for the developmentally challenged (CIG).

16 Rotavirus vaccines can be given to HIV+ infants regardless of CD4 counts unless another contraindication exists.

17 Infants whose mothers took monoclonal antibodies during pregnancy are ineligible for Pneu-P-23. Document an exemption as per Appendix 4.2.
VARICELLA IMMUNIZATION OF IMMUNOCOMPROMISED CLIENTS REQUIRES PHYSICIAN APPROVAL*

Varicella vaccine is available for susceptible immunocompromised persons listed below.¹ ²

Please check the appropriate bullet for your patient.

<table>
<thead>
<tr>
<th>Children and adults with:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Acute lymphocytic leukemia in remission for at least 12 months <em>(Varilrix only)</em> (total lymphocyte count must be ≥ 1.2 x 10⁹ /L and client not receiving radiation therapy at the time of immunization. If clients are still receiving maintenance chemotherapy, it should be withheld for at least 1 week before to 1 week after immunization).</td>
<td>□ Child and adult candidates for solid organ transplant. Administer last dose of vaccine 6 weeks before transplantation, providing the client is not receiving immunosuppressive treatment.</td>
</tr>
<tr>
<td>□ Asymptomatic HIV, CD4 ≥ 25% for age.</td>
<td>□ 2 or more years after HSCT transplant (providing there is minimal immunosuppression, and no graft vs. host disease).</td>
</tr>
<tr>
<td>□ Chronic kidney disease/dialysis</td>
<td>□ 3 or more months after remission of a malignant disease and the end of immunosuppressive treatment.</td>
</tr>
<tr>
<td>□ Other: ____________________________</td>
<td>□ 1 month after completion of high doses (&gt; 2 mg/kg or &gt; 20 mg daily) oral corticosteroid therapy more than 14 days duration.</td>
</tr>
</tbody>
</table>

Isolated immune deficiency

□ Humoral (IG) deficiency diseases
□ Neutrophil deficiency disorders
□ Complement deficiency diseases

* Primary care physician most familiar with the client’s current medical status or a medical specialist.

¹ Varicella susceptible is defined as:

- Lack of documented evidence of serological of VZV IgG antibodies; or
- Lack of documented evidence of immunization with 2 doses of a varicella-containing vaccine.

**NOTE:** verbal history of disease is unreliable and is not acceptable as of evidence of immunity for those born since January 1, 2003.

² Give 2 doses ≥ 3 months apart to immunocompromised persons ≥ 1 year old.

To be completed by physician* and sent to the local Public Health Centre

1) VZV IgG test result: ___________________________ Date of test: ___________________________

2) I have verified that as of the following date of __________________ (yyyy/mm/dd) this patient has no medical contraindications to the receipt of live attenuated varicella vaccine. I understand that persons 13 years of age and older require a second dose given 1 to 3 months after the first dose, and verify that this patient’s condition is sufficiently stable to permit receipt of both doses, if age appropriate.

Physicians signature: ___________________________ Clinic: ___________________________

Physician’s phone #: ___________________________ Fax #: ___________________________

To be completed by Public Health Nurse and faxed back to physician*:

Varicella Immunization(s) (2 doses if ≥ 13 years of age or if indicated):

Date: __________________ Lot #: _______________ Site _____ Initials: ___________________________

Date: __________________ Lot #: _______________ Site _____ Initials: ___________________________

Public Health Nurse’s name (print): _____________________________________________

Public Health Nurse’s phone #: ________________________________
### Appendix 7.3: MMR Immunization Referral Form

**MMR IMMUNIZATION OF IMMUNOCOMPROMISED CLIENTS REQUIRES PHYSICIAN APPROVAL**

Patient’s name: ____________________________________________________  Gender: M  F  
Patient’s DOB: ________________  Health Services #: __________________________  
(yyyy/mm/dd)

MMR vaccine is available for susceptible immunocompromised persons listed below. Please check the appropriate bullet for your patient.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Immunization Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSCT recipient (provided no GVHD, no suppressive treatment)</td>
<td>2 doses 2 months apart 1</td>
</tr>
<tr>
<td>Chronic kidney disease/dialysis</td>
<td>2 doses minimum 4 weeks apart 2</td>
</tr>
<tr>
<td>HIV/AIDS (if no significant compromise)</td>
<td>2 doses minimum 4 weeks apart 2</td>
</tr>
<tr>
<td>Solid organ transplant candidate</td>
<td>2 doses minimum 4 weeks apart 2</td>
</tr>
<tr>
<td>Asplenia / hyposplenia (congenital, surgical removal or functional)</td>
<td>2 doses minimum 4 weeks apart 2</td>
</tr>
</tbody>
</table>
| Isolated immune deficiency: (2 doses minimum 4 weeks apart) 2  
  o Humoral (Ig) deficiency diseases  
  o Neutrophil deficiency diseases  
  o Complement deficiency diseases | |
| 3 or more months after being cured of a malignant disease and the end of immunosuppressive treatment | 2 doses minimum 4 weeks apart 2 |
| 1 or more month after completion of high doses (> 2 mg/kg or > 20 mg daily) oral corticosteroid therapy | 2 doses minimum 4 weeks apart 2 |
| Other: _____________________________ | |

1 HSCT clients require re-immunization (2 doses) due to hematopoietic ablative therapy pre-transplant.  
2 Immunize according to age and past immunization history (e.g., if 1 dose previously received, give 1 more dose).

---

**To be completed by physician** and sent to the local Public Health Centre

I have verified that as of the following date of __________________ (yyyy/mm/dd) this patient has no medical contraindications to the receipt of live attenuated MMR vaccine. I understand verify that this patient’s condition is sufficiently stable to permit receipt of two doses.

Physicians signature: ____________________________  Clinic: ____________________________  
Physician’s phone #: ____________________________  Fax #: ____________________________

**To be completed by Public Health Nurse and faxed back to physician**:

MMR Immunization(s) (2 doses if indicated):  
Date: ________________  Lot #: ________________  Site _____  Initials: ________________________  
Date: ________________  Lot #: ________________  Site _____  Initials: ________________________  

Public Health Nurse’s name (print): ____________________________  
Public Health Nurse’s phone #: ____________________________
Appendix 7.4: High Dose Hepatitis B Immunization Algorithm - Renal, HIV, Congenital Immunodeficiency Deficiency [CID] Clients

*NOTE: If any dose in a series for those 16 and older is ENGERIX®-B, a 4-dose series must be given.

- **SUSCEPTIBLE:**
  - HBsAg: negative
  - anti-HBc: negative
  - anti-HBs: negative

  - Give initial HB series
  - Do not use min. intervals!

- **Acutely Infected:**
  - HBsAg: positive
  - anti-HBc: positive
  - anti-HBs: negative
  - IgM anti-HBc: positive

  - Infected and requires further clinical evaluation

- **Chronically Infected:**
  - HBsAg: positive
  - anti-HBc: negative
  - anti-HBs: negative
  - IgM anti-HBc: negative

- **Immune from Vaccination:**
  - HBsAg: negative
  - anti-HBc: negative
  - anti-HBs: positive with ≥ 10 IU/L

  - IMMUNE if:
    - anti-HBs: ≥ 10 IU/L

  - If anti-HBs remain < 10 IU/L:
    - Document as a non-responder.
    - Considered susceptible to HB infection.

  - If non-responder has been exposed (percutaneous or mucosal) to blood or body fluids:
    - Give 2 doses of HBig 1 month apart

- **RECOMBIVAX HB® (formulation varies):**
  - 0-15 years: 10 mcg 1 mL adult formulation at 0, 1, and 6 months.
  - 16-19 years: 10 mcg 1 mL adult formulation at 0, 1 and 6 months.
  - ≥ 20 years: 40 mcg (1 mL dialysis formulation) at 0, 1 and 6 months.

  - Test anti-HBs serology 1-2 months after last dose in initial series.

- **ENGERTIX®-B (20 mcg/mL adult formulation):**
  - 0-15 years: 20 mcg as 1 mL at 0, 1, and 6 months.
  - 16-19 years: 40 mcg as: A) two 1 mL injections 1 inch apart; OR B) one 2 mL injection at 0, 1, 2 and 6 months.*
  - ≥20 years: 40 mcg as: A) two 1 mL injections 1 inch apart; OR B) one 2 mL injection) at 0, 1, 2 and 6 months.
  - * Check for same lot #s and expiry dates.

  - IMMUNE if:
    - anti-HBs: ≥ 10 IU/L

- **RENAAL:**
  - Considered immune.
  - Annual anti-HBs testing is only appropriate once dialysis begins
  - Provide a booster dose HB vaccine if anti-HBs < 10 IU/L.

  - HIV / CID:
    - Considered immune.
    - Testing to be done at discretion of the client’s primary care provider / specialist.
    - Booster to be provided at the discretion of the client’s primary care provider / specialist.

  - Other:
    - HBsAg: negative
    - anti-HBc: positive
    - anti-HBs: negative

  - Considered immune.
  - Does not require further serology.

  - Test anti-HBs serology 1-2 months after last dose in initial series.

  - Give 1 dose and retest anti-HBs serology 1-2 months.
Appendix 7.5: Infant Hepatitis B Prophylaxis Record Referral Form

Note to physician/midwife/nursing staff delivering infant:

After giving the first injection of HB vaccine, please complete and return this form to the Regional Public Health or First Nations Inuit Health office of the parent/guardian’s region of residence. Regional health authority contact information is available [http://www.saskatchewan.ca/residents/health/accessing-health-care-services/immunization-services#immunization-forms-and-fact-sheets](http://www.saskatchewan.ca/residents/health/accessing-health-care-services/immunization-services#immunization-forms-and-fact-sheets)

### INFANT INFORMATION

<table>
<thead>
<tr>
<th>Name</th>
<th>Last Name</th>
<th>First</th>
<th>Health Services Number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of Birth</th>
<th>Sex</th>
<th>Birth Weight</th>
<th>grams</th>
</tr>
</thead>
<tbody>
<tr>
<td>yyyy/mm/dd</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**HOSPITAL/SITE OF DELIVERY**

<table>
<thead>
<tr>
<th>Physician/midwife Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### BIRTH MOTHER INFORMATION

<table>
<thead>
<tr>
<th>Name</th>
<th>Last Name</th>
<th>First</th>
<th>Middle</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of Birth</th>
<th>PHN</th>
<th>Postal Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>yyyy/mm/dd</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Immunization

<table>
<thead>
<tr>
<th>Immunization</th>
<th>Date (YY/MM/DD)</th>
<th>Lot Number</th>
<th>Panorama entered?</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB Ig 0.5 mL IM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>#1 HB 0.5 mL IM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Infant’s Family Physician or Pediatrician:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Postal Code</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**If placed for Adoption:**

<table>
<thead>
<tr>
<th>Parent(s) Name(s)</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**OR**

**Child and Family Services Social Worker:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTES:**

---

*Note: The form includes blank spaces for various details relevant to the infant's health, such as the name, date of birth, sex, birth weight, hospital/site of delivery, and family physician information. It also outlines the steps to be followed by the physician/midwife/nursing staff in delivering the infant.*
Appendix 7.6: Publicly Funded Immunization Schedule for Adult Post-Hematopoietic Stem Cell Transplant Recipients (autologous and allogeneic)

NOTE: The SCA endorses that this schedule is to be strictly followed by healthcare providers at determined intervals.

When questions or concerns arise that are related to the SCA’s HSCT immunization schedule, direct them to SCA.

<table>
<thead>
<tr>
<th>Vaccines 15</th>
<th>≥ 4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>10</th>
<th>12</th>
<th>14</th>
<th>18</th>
<th>20</th>
<th>≥ 24</th>
<th>26</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 (XBB.1.5)</td>
<td>● ¥</td>
<td>● ¥</td>
<td>● ¥</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza 2 (inactivated)</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneu-C-13</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tdap 2, 8, 17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV 2, 17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib 2, 17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HB 2, 11, 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV-9 14</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men B 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men-C-ACYW-135 2, 16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneu-P-23 4, 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR 4, 5, 6, 7, 9, 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabies series 13</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella 4, 5, 6, 7, 9, 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes zoster 15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¥ - All previously immunized or unimmunized patients should receive 3 doses (0, 4 weeks, 8 weeks) of XBB.1.5 as a primary series starting at 4 months post transplant (3 months post autologous transplant who are going onto maintenance therapy). If indicated, an additional dose should be given 3 months later. HSCT recipients with previous COVID-19 disease should defer vaccination 3 months post-infection.

1Starting at least 4 months after transplant regardless of graft versus host disease (GVHD) or immunosuppressant therapy. High dose flu vaccine is publicly funded only for those 65 years and older.

2Vaccination should be at least 2 months after last dose of IVIG.

3One Pneu-P-23 booster after 5 years.

4No immunosuppressant therapy in preceding 1 year (cyclosporine, tacrolimus, prednisone, methylprednisone, ruxolitinib).

5No rituximab therapy preceding 6 months.

6No chemotherapy preceding 3 months.

7Patients receiving lenalidomide or velcade maintenance therapy may receive MMR and varicella vaccination.

8Tdap booster every 10 years.

9Refer to Chapter 7, Immunization of Special Populations, for Var and MMR referral forms.

10Vaccination should be at least 8 months after last dose of IVIG.

11Refer to SIM Appendix 7.4 High Dose Hepatitis B Immunization Algorithm - Renal, HIV, Congenital Immunodeficiency Client.

12Repeat series if response is less than 10 IU/mL after series completion.

13Post vaccination antibody testing required 1-2 months after 3rd dose. For patients who do not respond to primary vaccine series a second 3 dose series should be administered. Other post vaccination antibody testing not required due to lack of evidence regarding revaccination.

14Pre-exposure prophylaxis is not publicly funded. Recommended only for those considered high risk (e.g., veterinarians, veterinary health technicians, animal shelter workers, animal control workers, etc.). Rabies titre should be checked at 1 year for high risk patients to assess immune status prior to vaccination to see if it is required. Refer to CDC manual https://www.ehealthsask.ca/services/Manuals/Pages/cdcmanu.aspx.

15Publicly funded for patients aged 18-26 years old. NOT publicly funded for older patients.

16The following vaccines are not publicly funded at this time, even though they may be recommended by the transplant program:

- Shingrix® (non-live recombinant Herpes zoster vaccine) is the only Herpes zoster vaccines approved for immune compromised individuals who are ≥ 18 years old, are VZV seropositive, who have not had a shingles infection within 1 year AND are at least 6 months post autologous stem cell transplant; or 2 years post allogeneic stem cell transplant and are > 12 months off immunosuppression and no flare of GVHD.
- HPV vaccines for those ineligible for publicly funded HPV-9
- VAXNEUVANCE® (Pneu-C-15)  Prevnar 20™ (Pneu-C-20)  Arexvy or Ablynvy RSV vaccines

16Booster every 5 years.

17DTaP-IPV-Hib may be administered off label to HSCT recipients (whose age is beyond the vaccine’s licensed age range) to reduce the number of injections they require to meet the antigen requirements as noted in this schedule.
Appendix 7.7: Tdap Immunization Decision Chart for Pregnant Women

Has the pregnant woman received Tdap **during this pregnancy**?

- **NO**
  - Recommend and offer her one Tdap dose, ideally between 27 to 32 weeks gestation.
  - Tdap can be given between 13 to 26 weeks gestation in some situations (possible pre-term delivery or travel).
  - Tdap does not need to be repeated during this pregnancy, even if it was received before 13 weeks gestation.

- **YES**
  - She does not require another Tdap dose during this pregnancy or post-partum.
Appendix 7.8: Publicly Funded Immigrant and Refugee Immunization and Serology Recommendations

- Refer to Chapter 5, Immunization Schedules for routine vaccine schedules.
- Refer to Chapter 7, Immunization of Special Populations for risk factors.
- Refer to Chapter 10, Biological Products for specific vaccine indications and information.

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Serology</th>
<th>0-17 years of age</th>
<th>≥ 18 years of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>Not recommended</td>
<td>Refer to Publicly Funded HA Vaccine Indications</td>
<td>Refer to Publicly Funded HA Vaccine Indications</td>
</tr>
<tr>
<td>HB</td>
<td>Recommended ² 1. HBsAg 2. HBsAb (Anti HBs) 3. Hep B Total Core Ab (Anti Hbc total)</td>
<td>Refer to Publicly Funded HB Vaccine Indications</td>
<td>Refer to Publicly Funded HB Vaccine Indications</td>
</tr>
<tr>
<td>HC</td>
<td>Recommended ³ Anti-Hep C</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Varicella</td>
<td>Refer to Appendix 5.4 Publicly Funded Varicella Immunization Eligibility</td>
<td>Refer to Appendix 5.4 Publicly Funded Varicella Immunization Eligibility</td>
<td>Refer to Appendix 5.4 Publicly Funded Varicella Immunization Eligibility</td>
</tr>
<tr>
<td>Measles</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Mumps</td>
<td>Not recommended</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Rubella</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Tetanus</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Diphtheria</td>
<td>Not recommended</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Pertussis</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Polio</td>
<td>Not recommended</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hib</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>HPV</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Influenza</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Men-B4C</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Men-C-ACYW-135</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Men-C-C</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Pneu-C-13</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Pneu-P-23</td>
<td>Not applicable</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Not applicable</td>
<td>●</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

¹ Individuals who do not have documented immunization records should be referred to Public Health.

²A Screen adults and children from countries where the seroprevalence of chronic HB infection is ≥2% for all 3 markers (Pottie et al., 2011).

²B HB vaccination can occur prior to specified serology being completed. There should be a minimum of 1 month between a HB vaccine and HBsAg test to avoid false positive result. Complete the HB immunization series if serology results are received during the series unless the HBsAg or Anti Hbc total come back positive. Once the HB vaccine series is completed, HBsAb can be drawn 1 month after the last dose.

³ Recommended if HC prevalence in country of origin is >3%. If HC positive then, automatic testing for HA & HB immunity is done at RRPL. Go to map at: https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/hepatitis-c#4677.
Appendix 7.9: Publicly Funded Immunization Schedule for Adult Solid Organ Pre-Transplant Candidates

- Solid organ transplants include: heart, lung, kidney, liver, pancreas, small bowel and islet cells. These guidelines do not apply to skin, bone and cornea transplants since these are tissue transplants and do not require immunosuppression.
- Immunize adults pre-SOT with routine vaccines as stated in SIM chapter 5 Sections 1.6, 1.7 and 2.1. Use minimum intervals if required. Completed series are not to be re-offered.
- When possible, ensure required vaccine series are completed pre-SOT (2 weeks for inactivated and mRNA COVID-19 vaccines; 4 weeks prior to immunosuppression and 4 weeks prior to transplant for live vaccines).
- Avoid inactive vaccines for at least 6 months and live vaccines at least 12 months after completion of treatment with biological agents such as Rituximab. If a patient does not present with a clearance letter, please contact the transplant agency for this letter.
- Post-immunization titres not recommended unless noted.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose 1 date</th>
<th>Dose 2 date</th>
<th>Dose 3 date</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 XBB.1.5 mRNA</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>HA 1</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>HB (high dose) 1,2</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Hib 3</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>HPV-9 4</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Influenza 5</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>IPV 6</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>MMR 7,8A,8B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men B 9</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Men-C-ACYW-135 9,10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneu-C-13 11</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Pneu-P-23 12</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Tdap 6,13,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Var 7,8A,8B</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

Unvaccinated pre-transplant SOT candidates should receive 3 doses (0-4 weeks-8 weeks) of mRNA vaccine as a primary series, with the final dose given 1-2 weeks prior to transplantation whenever possible. If indicated, an additional dose should be given 3 months later.

1 Liver transplant only or if other publicly funded HA vaccine risk factors apply. Dose 2 min. 24 weeks later.
2 Refer to SIM Appendix 7.4 High Dose Hepatitis B Immunization Algorithm - Renal, HIV, Congenital Immunodeficiency Client. Repeat series if response is less than 10 IU/mL after series completion.
3 1 dose for those 5 years of age and older regardless of Hib immunization history or disease, and at least 1 year after any previous Hib dose.
4 Publicly funded up to 26 years old. Not publicly funded if starting series after 27 years old. Min. 4 weeks between doses 1 & 2. Min. 12 weeks between doses 2 and 3. There must be 24 weeks between doses 1 and 3.
5 Inactivated influenza vaccine annually. High dose influenza vaccine is only publicly funded those 65 years and older.
6 Min. 4 weeks between doses 1 and 2. Min interval 24 weeks between doses 2 and 3.
7 Live vaccines are contraindicated for post-SOT recipients.
8a Provide series if no evidence of immunity. Give dose #1 ≥ 10 weeks pre-SOT and dose #2 4 weeks later and a minimum 4 weeks pre-SOT.
8b Immunity serology done pre-SOT as per requesting physician prior to vaccine administration and 4 weeks post-series administration.
9 Min. 4 weeks between doses 1 and 2.
10 Some may have received dose 1 as an adolescent (e.g., Grade 6) and just require 1 additional dose.
11 1 dose pre-SOT 8 weeks before Pneu-P-23. Pneu-C-13 series should be administered at least one year after any previously administered dose of Pneu-P-23.
12 An 8-week interval is required when Pneu-C-13 was given before Pneu-P-23. Only 1 booster given ≥5 years from first dose.
13 Tdap booster every 10 years.
14 The following vaccines are not publicly funded at this time, even though they may be recommended by the transplant program:
- HPV vaccines for those ineligible for publicly funded HPV-9
- Shingrix® (non-live recombinant Herpes zoster vaccine)
- VAXNEUVANCE® (Pneu-C-15)
- Prevnar 20™ (Pneu-C-20)
- Arexvy or Abrysvo RSV vaccines
Appendix 7.10: Publicly Funded Immunization Schedule for Adult Solid Organ Post-Transplant Recipients

- Solid organ transplants include: heart, lung, kidney, liver, pancreas, small bowel and islet cells. These guidelines do not apply to skin, bone and cornea transplants since these are tissue transplants and do not require immunosuppression.
- Immunize adults post-SOT as stated in SIM chapter 5 Sections 1.6, and 1.7, and 2.1.
- Vaccine series are not to be restarted post-SOT. Some pre-transplant immunity is retained, although it may be reduced, thus re-immunization is NOT indicated for SOT recipients. Assess their previous immunization history and offer non-live vaccines to complete routine schedules.
- Live vaccines are contraindicated for post-SOT recipients.
- Avoid inactive vaccination for at least 6 months after completion of treatment with biological agents such as Rituximab (3 months for COVID-19 mRNA vaccine) or anti-thymocyte treatments such as anti-thymocyte thymoglobulins. If a patient does not present with a clearance letter, please contact the transplant agency for this letter.
- Immunization may resume once the individual is on baseline immunosuppression, usually 6 to 12 months post-SOT, and as determined appropriate by the individual’s attending transplant physician. Immunizations (e.g., inactivated influenza, COVID-19) could begin as early as 3 months post-SOT in certain circumstances as determined by the transplant physician or during an outbreak.
- Post-immunization HB titres are recommended as per SIM Appendix 7.4: High Dose Hepatitis B Immunization Algorithm - Renal, HIV, Congenital Immunodeficiency Clients.
- Refer to the Communicable Disease Control Manual at https://www.ehealthsask.ca/services/Manuals/Pages/cdmanual.aspx for post-exposure recommendation (e.g., measles, rabies, varicella).

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>1</th>
<th>2</th>
<th>≥ 3</th>
<th>≥ 6</th>
<th>7</th>
<th>8</th>
<th>12</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 XBB.1.5 mRNA</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
</tr>
<tr>
<td>HA 1</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
</tr>
<tr>
<td>HB (high dose) 1, 2</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib 3, 12</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV-9 4</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza 5</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV 6, 12</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men B 7</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men-C-ACYW-135 8</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneu-C-13 9</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneu-P-23 10</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dtap 11, 12</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Unvaccinated pre-transplant SOT recipients should receive 3 doses (0-4 weeks-8 weeks) of mRNA vaccine as a primary series. If indicated, an additional dose should be given 3 months later. Vaccinated SOT recipients should receive an additional dose 3 months after their previous vaccine dose. All SOT recipients should wait at least 1-month post-transplant to continue vaccine series, regardless of induction therapy. SOT recipients undergoing active treatment for acute rejection should defer vaccination for 1 month. SOT recipients with previous COVID-19 infection should defer vaccination for 3 months post-infection.

1 Liver transplant only or if other publicly funded HA vaccine risk factors apply. Dose 2 min. 24 weeks later.  
2 Refer to SIM Appendix 7.4 High Dose Hepatitis B Immunization Algorithm - Renal, HIV, Congenital Immunodeficiency Clients. Repeat series if response is less than 10 IU/mL after series completion.  
3 1 dose for those 5 years of age and older regardless of Hib immunization history or disease, and at least 1 year after any previous Hib dose.  
4 Publicly funded up to 26 years old. Not publicly funded if starting series after 27 years old. Min. 4 weeks between doses 1 & 2. Min. 12 weeks between doses 2 and 3. There must be 24 weeks between doses 1 and 3.  
5 Inactivated influenza vaccine annually. High dose influenza vaccine is only publicly funded those 65 years and older.  
6 Min. 4 weeks between doses 1 and 2. Min interval 24 weeks between doses 2 and 3.  
7 Min. 4 weeks between doses 1 and 2.  
8 Some may have received dose 1 as an adolescent (e.g., Grade 6) and just require 1 additional dose.  
9 1 dose post-SOT, 8 weeks before Pneu-P-23. Pneu-C-13 series should be administered at least one year after any previously administered dose of Pneu-P-23 (if not administered pre-SOT).  
10 An 8-week interval is required when Pneu-C-13 was given before Pneu-P-23. Only 1 booster given ≥5 years from first dose.  
11 Tdap booster every 10 years.  
12 DTap-IPV-Hib may be administered off label to solid organ transplant recipients (whose age is beyond the vaccine’s licensed age range) to reduce the number of injections they require to meet the antigen requirements as noted in this schedule.  
13 The following vaccines are not publicly funded at this time, even though they may be recommended by the transplant program:
   • HPV vaccines for those ineligible for publicly funded HPV-9
   • Shingrix® (non-live recombinant Herpes zoster vaccine)
   • VAXNEUVANCE® (Pneu-C-15)
   • Prevnar 20™ (Pneu-C-20)
   • Arexvy or Abrivyo RSV vaccines